


INSTITUT DU CERVEAU
ET DE LA MOELLE ÉPINIÈRE
ICM BRAIN & SPINE INSTITUTE, PARIS

ANNUAL REPORT 2016

SEARCH, FIND, CURE, FOR YOU & WITH YOU.







Sharing leads to progress

PROFESSOR GÉRARD SAILLANT, ICM PRESIDENT

6

ICM, AN INNOVATIVE AND UNIQUE MODEL

14



WHAT DOES IT MEAN TO DO RESEARCH TODAY?

34



THANK YOU

86

SUMMARY

- Conversation with the President *p.6*
- Conversation with the Chief Executive *p.8*
- Conversation with the Chief Executive of the IHU-A-ICM *p.10*

THE INSTITUTE

- ICM, an innovative and unique model *p.14*
- Our missions *p.16*
- Our values *p.18*
- Our scientific priorities *p.20*
- Highlights and major breakthroughs in 2016 *p.22*
- Women and men *p.24*
- Governance *p.28*

MISSION

- A key player at the heart of 21st century challenges *p.32*
- What does it mean to do research today? *p.34*

CUTTING-EDGE RESEARCH

- Research programs *p.36*
- Research teams *p.40*
- Overview and publication examples *p.44*
- Synergy *p.50*
- Awards and distinctions *p.52*

TEACHING AND TRAINING *p.54*

NATIONAL AND INTERNATIONAL COLLABORATION *p.56*

CLINICAL RESEARCH

- Center for Clinical Investigation *p.58*
- Nervous System Diseases Center *p.60*

KNOWLEDGE SHARING & INNOVATION

- Research & Technology Development Office *p.62*
- Living Lab & Findmed *p.64*
- iPEPS-ICM incubator *p.66*

SUPPORT OUR MISSION

- State-of-the-art technological platforms *p.70*

DILIGENCE AND TRANSPARENCY AT THE HEART OF OUR ACTIONS

- Financial situation in 2016 *p.76*


COMMUNICATION AND PHILANTHROPY

- Le Cercle des Amis de l'ICM *p.84*
- Communication *p.86*
- Thank You *p.88*

CONVERSATION WITH
THE PRESIDENT

PROFESSOR
GÉRARD SAILLANT

*To find,
we must first
understand.*



The Brain and Spine Institute came to life six years ago. When we first came up with the idea for the Institute with our founding members and institutional partners, we never imagined it would be such a success. It was a truly daring project. Bringing all the key players in research on nervous system diseases together, in one place, illustrates just how involved everyone is, and how talented.

I would like to take this opportunity to thank our partners, our researchers and the entire staff at the Institute for their immense and unwavering support, as well as our donors for their renewed generosity.

Our 2016 Report is more than a look at the past year: it is a tribute to those that made our projects possible.

2016 for ICM proved our Institute's vitality and its involvement in the world's great healthcare challenges. International collaboration, scientific breakthroughs, sharing of knowledge, as well as numerous awards show how multi-faceted this major player of French research really is.

Current stakes in research on brain illnesses are extremely high, especially as our population ages, and society as a whole is faced with the challenge of "ageing well". ICM has a large role to play so that each and every one of us is able to age in the best possible conditions, maintaining a form of freedom in our actions.

We do not know all that much about this fascinating yet complex organ we call the brain!


There is so much left to explore. To find, we must first understand. To get there, we need you, and your support.

Thank you, truly.

CONVERSATION WITH
THE CHIEF
EXECUTIVE

PROFESSOR
GÉRARD SAILLANT

*Together,
we will be able
to face future
challenges.*



Our Institute brings together diverse women and men from various horizons, where skills and knowledge intertwine.

This represents an incredible collective wealth. It brings out the best, giving us the opportunity to meet upcoming challenges together.

ICM combines a critical mass of talented researchers and clinicians who, in their synergy, develop a translational approach to research. The Institute's location in Paris, at the heart of the Pitié-Salpêtrière Hospital with over 100,000 patients every year, encourages researchers and clinicians to interact. Thanks to the diversity of our activities and the plurality of our expertise, we can take on the challenge of understanding the nervous system. The multidisciplinary approach developed at ICM, along with our risk-taking and technological innovation, are strong assets for scientific and medical research.

ICM is one of a kind. It is open to visitors from around the world, to students, to researchers, and more.

Today, more than ever, it is time to open up, encourage creativity, focus on cooperation, collaboration, and share our respective territories.

It will not prevent us from rising up to the challenge, and it will not prevent us from stimulating the quest for quality, performance and discoveries. Quite the contrary... What brings us, researchers, students, doctors, technicians, engineers, together is our essential role in this shared mission for the world as a whole.

Results from 2016 give our actions meaning and confirm our community's excellence. These results show that ICM is dynamic, attractive, with exceptional talent, with a demanding strategy and actions taken, in a high-quality work environment. Tangible progress has been made: a balanced budget, on the rise, over 540 scientific publications including 115 with an impact factor over 7, 11 ANR contracts awarded, prototypes designed in our Living Lab, as well as numerous distinctions and awards for our researchers and the hosting of new startups.

2016 also marks the official launch of our roadmap for the years to come. Priorities have been set to maintain, and go beyond, our excellent level. New teams, talented researchers, development of clinical research, instruments for precision medicine, promoting excellence in neuroscience and nervous system illness training and education, new instruments to encourage entrepreneurship, and development of national and international partnerships: these make up the foundation needed to accomplish our missions, reach our goals and to become a vital partner in the development of innovative therapy.

In 2017, we must stay on track and consolidate our community's excellence and skill in producing knowledge as well as breakthrough discoveries.

I would like to extend a very warm thank you to all the individuals who, every single day, contribute to our venture: the 650 women and men at the Institute, our partners, donors, and our volunteers, for their immense support.

CONVERSATION WITH
THE CHIEF EXECUTIVE
OF THE IHU-A-ICM

FRÉDÉRIC
SALAT-BAROUX



“ We are doing everything we can to increase prevention and treatment of nervous system diseases. ”

The IHU-A-ICM's mission is to lead a high-level project for patient care, training, and technology transfer in the field of nervous system diseases research. Its priority is to encourage the development of innovative preventive, diagnostic, and therapeutic products and processes. The results of these past four years have been overwhelmingly positive. They allowed us to develop international-level research focused on nervous system diseases, on neurology and psychiatry, to create cutting-edge technological platforms, to implement research partnerships with industry players, to train future healthcare professionals, to implement international teaching programs, to carry out large-scale clinical trials for many nervous system diseases through participation in national, European and international networks and to transfer patient care from the hospital to back home.

Within the IHU-A-ICM mid-term assessment and on request by the International IHU Jury, the IHU-A-ICM developed a roadmap with a long-term action plan. IHU-A-ICM and ICM founding members came to an agreement on a strategic plan, approved by the International IHU Jury and General Investment Commission (Commissariat Général à l'Investissement - CGI) in November 2016 following a site visit on October 18, 2016. This approval allows the IHU-A-ICM to carry out its strategic plan around eight main topics: recruiting new teams, learning and training, neuroinformatics, industrial promotion, clinical research, cellular and molecular imaging, big brain theory program (transversal internal projects with high potential) and fundraising to meet its ambitious goals.

2016 was a year filled with success, including ambitious clinical trials. The INSIGHT study in partnership with Pfizer, an innovative study on Alzheimer's disease, is one of the first worldwide to monitor at-risk healthy individuals, with high hopes in gaining a better understanding of the disease. The ICEBERG cohort is at the heart of the IHU's Parkinson's project, which aims at studying predictive conversion and progression factors of Parkinson's disease. We are making progress in major projects on Alzheimer's disease, Parkinson's disease, multiple sclerosis to identifying myelin repair strategies, epilepsy to understand and anticipate seizures and behavioral disorders that come into play in many neurological illnesses.

Finally, this year a joint ICM and IHU-A-ICM internal call for high-risk projects made it possible to develop fifteen innovative and unique transversal projects, among which the DYNAMO project that aims at creating a digital model for cerebral evolution in Alzheimer's disease. With time, the project hopes to develop a high-precision predictive medicine instrument. Another noteworthy project is the IncPD project, that is exploring unknown parts of DNA involved in Parkinson's disease.

IHU-A-ICM FOUNDERS



THE INSTITUTE

THE BRAIN AND SPINE INSTITUTE (ICM) IS AN INTERNATIONAL RESEARCH CENTER, ONE OF A KIND THROUGHOUT THE WORLD THANKS TO INNOVATION AT THE HEART OF ITS DESIGN AND ORGANIZATION. THE INSTITUTE'S GOAL, AS IT BRINGS TOGETHER PATIENTS, PHYSICIANS, RESEARCHERS AND ENTREPRENEURS IN ONE PLACE, IS TO ALLOW RAPID DEVELOPMENT OF TREATMENT FOR NERVOUS SYSTEM DAMAGE IN ORDER TO MAKE IT AVAILABLE TO PATIENTS AS EARLY AS POSSIBLE. THE WORLD'S BEST SCIENTISTS, HAILING FROM A DIVERSITY OF BACKGROUNDS AND COUNTRIES, ARE IN CHARGE OF DEVELOPING CUTTING-EDGE RESEARCH AT THE INSTITUTE. TO GIVE RESEARCHERS THE OPPORTUNITY TO TAKE THEIR WORK TO THE NEXT LEVEL AND PROVIDE HOPE TO PATIENTS.



ICM, an innovative and **unique** model *p.14*

Our **missions** *p.16*

Our **values** *p.18*

Our scientific **priorities** *p.20*

Highlights and **major breakthroughs** in 2016 *p.22*

Women and men *p.24*



Governance *p.28*



ICM STORY OVER THE YEARS...

FACED WITH WORLD HEALTHCARE CHALLENGES IN THE FIELD OF NERVOUS SYSTEM DISEASES AND TRAUMA, WITHOUT EFFECTIVE TREATMENT TO ERADICATE THEM, AND GIVEN THE RISE IN LIFE EXPECTANCY, INNOVATION IS A NECESSITY.

VISIONARIES EAGER TO CREATE A NEW KIND OF ECONOMIC MODEL BASED ON STRONG PUBLIC AND PRIVATE PARTNERSHIPS CAME TOGETHER: THE FOUNDING MEMBERS OF ICM, INCLUDING CURRENT PRESIDENT PROFESSOR GÉRARD SAILLANT, JEAN TODT, PROFESSOR LYON-CAEN, AND PROFESSOR YVES AGID, EMBARKED WITH OUR PARTNERS ON THE INCREDIBLE ADVENTURE OF DESIGNING A NEUROSCIENCE INSTITUTE CAPABLE OF FACING THIS MAJOR CHALLENGE OF OUR TIME.



RESEARCH WHERE INNOVATION DRIVES ORGANIZATION

FROM A SCIENTIFIC STANDPOINT, ICM APPROACH IS INNOVATIVE WITH A SEAMLESS, OPEN APPROACH TO RESEARCH. RESEARCH TEAMS ARE INDEPENDENT YET LINKED TOGETHER THANKS TO TRANSVERSAL RESEARCH PROGRAMS THAT ALLOW FOR SKILL SHARING.

FROM THE INFINITELY SMALL...

Fundamental research is research turned towards a discipline's fundamental fields. This encompasses scientific research that does not have a pre-determined financial goal when it is conducted. However, this approach is essential: it is what allows us to learn about and understand how bodily systems function.

...TO THE INFINITELY LARGE

Clinical research places individuals at the heart of this all-too-rare approach. Subjects, whether ill or healthy, take part in protocols that help us increase our knowledge of a certain pathology or treatment.

ONE SINGLE DIRECTION

Translational research is the essential link between fundamental and clinical research. It allows patients to benefit from diagnostic and therapeutic innovation more quickly. Translational research forms the basis of all research conducted at ICM. Bringing these three activities under one roof, in one single direction, means quicker discovery of new treatments.


4 MAJOR SCIENTIFIC FIELDS

Molecular and Cellular Neuroscience
Integrated Neurophysiology
Cognitive Neuroscience
Clinical and Translational Neuroscience

ALONGSIDE TRANSVERSAL TOPICS

Neurogenetics
Neuroimmunology
Stem Cells and Repair
Motor Neurons: from cell bodies to synapses
Study of organelles in neurodegenerative illnesses
Study of proteinopathies and propagation mechanisms
Multimodal data analysis
Rare neurological disease treatment methodology

GLOBAL RESEARCH THAT COVERS THE EXPANSE OF BRAIN AND SPINE DISEASES



KEY FIGURES FOR 2016

1 LIVING LAB



649 researchers and clinicians

22 000 SQM

17 CUTTING-EDGE TECHNOLOGICAL PLATFORMS

8 floors

26 RESEARCH TEAMS

147631 DONORS

13 INNOVATIVE STARTUPS

276 doctoral and post-doc students



32 countries represented

65 clinical trials

2016 HIGHLIGHTS



Over 600 publications in major international journals

BASSEM HASSAN

INTERNATIONALLY-RENOUNDED RESEARCHER joins ICM

11

INSTITUTE RESEARCHERS rewarded for excellence in their work

ICM RECEIVES "CARNOT 3" CERTIFICATION



3RD PLACE IN THE 2016 BIG DATA INNOVATION TROPHY

BRAIN TO MARKET SUMMER SCHOOL IS A SUCCESS

VISIT OF ICM BY THE FRENCH PRESIDENT

OUR VALUES

THE DRIVING VALUES OF ICM,
THE FOUNDATION OF EVERYTHING WE DO,
ARE AN APPROPRIATE RESPONSE
TO THE NEED FOR CUTTING-EDGE RESEARCH
ON NERVOUS SYSTEM DISEASES.



SCIENTIFIC EXCELLENCE

The best researchers are involved with a common goal: to discover

FIRST AND FOREMOST FOR THE PATIENT

Bringing patients, physicians researchers and entrepreneurs
together to advance more rapidly than illness

FLEXIBILITY

To let scientific creativity express itself

OPENNESS

Create a place for sharing, to encourage interaction
with the greater community and industry partners

PASSING ON KNOWLEDGE

On an national and international level

ACCELERATE

To apply tomorrow's solutions as early as possible

SCIENTIFIC PRIORITIES TO DELIVER ON CHALLENGES

PREVENT MEANS INHIBITING ILLNESS AND ITS APPEARANCE.

TREAT MEANS SLOWING DOWN OR STOPPING PATHOLOGICAL EVOLUTION.

REPAIR MEANS REBUILDING NEURAL CIRCUITS AFTER DAMAGE TO THE NERVOUS SYSTEM.

RELIEVE TO ALLEVIATE OR ELIMINATE SYMPTOMS SUCH AS MEMORY LOSS, LANGUAGE DISORDERS, PAIN, ANXIETY, DEPRESSION...

THE GOAL IS TO PRODUCE INTERNATIONAL-LEVEL RESEARCH BY COMBINING SCIENTIFIC CREATIVITY AND THERAPEUTIC PURPOSE


ICM'S SCIENTIFIC PROGRAM IS BASED ON THE FOLLOWING VALUES:

- Create a research "strike force", leading to recruitment of the best French researchers ranked by the High Council of Research Evaluation and Higher Education (HCERES) and the best international investigators evaluated by the International Council for Science
- Make cutting-edge technology research platforms available as well as a high-performance Center for Biological Resources
- Develop multidisciplinary "translational" research, in collaboration with industry partners and the best research centers throughout France and the world.
- Define priority research areas.

YOUR BRAIN, OUR PRIORITY

TOGETHER, ICM'S 650 RESEARCHERS, ENGINEERS AND TECHNICIENS ARE WORKING TO:


- Diagnose neurodegenerative diseases earlier
- Predict their progress and improve treatment
- Develop new diagnostic instruments
- Detect new markers
- Model disease progression to diagnose illness earlier and anticipate treatment
- Offer personalized treatment
- Delay disease progression
- Repair affected cells
- Explore new research on causes and mechanisms involved in neurodegenerative diseases
- Study neural development mechanisms to answer the following question: why do some brains lose their homeostatic capability, setting the stage for neurodegenerative diseases?



OUR SCIENTIFIC STRATEGY


8 PRIORITY AREAS FOR 2016-2025

- RECRUIT new teams
- DEVELOP COLLABORATION amongst teams and ENCOURAGE A MULTIDISCIPLINARY APPROACH to test new scientific hypotheses in an open-minded setting
- EMPHASIZE CLINICAL RESEARCH to succeed, within 3 years, in offering new clinically-approved treatment options to patients
- ACCELERATE DEVELOPMENT OF NEUROINFORMATICS and implement tools for a more predictive form of medicine, with a more quantitative approach in diagnosis, prognosis and treatment
- PROMOTE eXCELLENCE IN EDUCATION AND KNOWLEDGE TRANSFER in neuroscience and the field of nervous system diseases. Our ambition is to create a place of learning when interactions are transdisciplinary
- REINFORCE SERVICES FOR INCUBATED STARTUPS to help them with more rapid financing to get products to market more quickly
- MAKE CUTTING-EDGE EQUIPMENT AVAILABLE TO RESEARCH TEAMS as needed for their research to remain competitive on an international level, stay ATTRACTIVE to build NATIONAL AND INTERNATIONAL PARTNERSHIPS needed to carry out our missions and meet our goals
- REINFORCE FUNDRAISING ACTIVITIES



12 MONTHS OF PROGRESS AND DEFINING MOMENTS

WHAT TO TAKE AWAY FROM OUR KEY MOMENTS



PUBLICATIONS ON THE RISE!
540 publications in major international journals

A WORLD-CLASS RESEARCHER JOINS ICM

Bassem Hassan, neuroscientist, joined ICM in January 2016. He leads the "Brain Development" team and is focused on genetic mechanisms that control early nervous system development, from cell specification to neural network development, and on processes involved in neurological diseases.



CLEVEXEL PHARMA PHARMA AND ICM IN THE FIGHT AGAINST PARKINSON'S DISEASE

ICM and pharmaceutical company Clevexel Pharma, directed par Christian Bloy, signed a partnership deal to develop **new treatment** against central nervous system diseases and, more specifically, **Parkinson's disease**.

A GOOD RECORD FOR ANR PROJECTS

ICM teams were awarded **11 ANR projects**: 3 as coordinator and 8 as partner in 2016 for a total of 2,806,588 € versus 2 projects awarded in 2015. Additionally, **30 projects** were submitted this year, versus 23 in 2015.

2 806 588 €

THE FRENCH PRESIDENT VISITS ICM

French President **François Hollande** was present at ICM during International University-Medical Center Institute (IHU) Day. He attended a presentation of ICM by the management team and a presentation of the research done by three researchers and clinicians: **Claire Wyart**, **Lionel Naccache**, and **Carine Karachi**. He also visited the **Magnetoencephalography (MEG)** platform with **Nathalie George**.



ICM RECEIVES "CARNOT 3" CERTIFICATION

ICM received Carnot certification renewal, as part of the "Carnot 3" program. Carnot Institutes are major players when it comes to supporting public research institute development and relationships with businesses. This certification will increase exposure in order to implement **large-scale research projects** at ICM and **accelerate discovery and commercialization** of patient treatments.



LIVING LAB AT THE PARIS VIVA TECHNOLOGY CHALLENGE

The **uCIL Living Lab**, launched at ICM in 2015, participated in the first edition of the Paris Viva Technology Challenge that aims to bring **investors and managers** of innovative companies together along with startups from around the world. The uCIL Living Lab is involved in coming up with **innovations, technology, products, and services** to assist with real-life needs in healthcare in the fields of **neurology and psychiatry**.



BRAIN TO MARKET SUMMER SCHOOL

The "Brain to Market" Summer School, from August 29th to September 2nd 2016 at ICM, combined **translational neuroscience** and **entrepreneurial learning** in an intensive training program. This year, participants worked on **epilepsy**.

THE BRITISH MINISTER FOR LIFE SCIENCES VISITS ICM

George Freeman, British Minister for Life Sciences, was welcomed to ICM by **Alexis Brice**, ICM and IHU-A-ICM Chief Executive. During their meeting, Minister Freeman and Professor Brice covered ICM's **model and organization** as well as research and **development topics, Big Data, industry relations and accelerated access to the innovative products market**.



3RD PLACE IN THE 2016 BIG DATA INNOVATION TROPHY

BioSerenity, specialized in smart healthcare solutions and connected medical equipment and **Dataiku**, **producer of Big Data project acceleration program Dataiku DSS**, won third place for their Metadata. Lab project in the 2016 Big Data Innovation Trophy. The project, developed with support from the **Brain and Spine Institute -ICM** and **Télécom ParisTech**, aims at speeding up diagnosis of epilepsy patients: it uses smart clothing developed by BioSerenity to collect patient health data, which is then analyzed using the predictive analysis platform developed by Dataiku.



2016 – 2025

LAUNCH OF OUR ROADMAP

ICM's strategy is focused on 8 major areas: **recruitment of new teams, learning & training, neuroinformatics, commercialization, clinical research, cellular & molecular imaging, big brain theory program, and fundraising**.

A COMMUNITY DEDICATED TO NEUROSCIENCE

ICM IS, FIRST AND FOREMOST, A HUMAN ADVENTURE, A COMMUNITY OF EXPERTS THAT ARE ACTIVELY INVOLVED IN FIGHTING AGAINST NERVOUS SYSTEM DISEASES ON A DAILY BASIS.

Researchers, doctors, biologists, pharmacologists, mathematicians, engineers, physicians, programmers, technicians, paramedical staff, support staff... ICM brings together multidisciplinary individuals who work hand in hand. Thanks to close collaboration between researchers and doctors, patients benefit from diagnostic and therapeutic innovations more rapidly. ICM's strength lies in the interaction between experts of different fields and the pooling of their skills to discover treatments as fast as possible.



"I develop far-reaching translational research projects. I discovered just how enriching it could be to bring fundamental and clinical research together. I decided to join ICM after several years doing research in a major London lab. The quality of my work changed drastically, because I now interact with neurobiologists and pharmacologists on a daily basis who bring different approaches to the table. I'm passionate about this kind of interaction. By bringing their knowledge on fundamental mechanics with my clinical results, I have the opportunity to develop actual translational research projects with quicker progress. ICM is truly unique!"

BENEDETTA BODINI,
INSERM NEUROLOGIST
AND RESEARCHER AT ICM



I work with patients with spinal damage. The future seems to lie in the ability to blend energy and knowledge. ICM is at the heart of the hospital, a couple feet away from the orthopedic and trauma department I am in charge of. This geographical proximity is very practical: it's that simple! Given how complex my schedule is at the hospital, it allows me to participate in fundamental research on the spinal cord developed at ICM. Surgeons and researchers are mutually enriching thanks to our knowledge and different approaches towards science and progress. It's exceptional to be able to go from the operating room and patient appointments to laboratory study of the spinal cord. I am absolutely positive that our interactions will benefit patients."

PROFESSOR HUGUES PASCAL-MOUSSELD,
ORTHOPEDIC SURGERY AND
TRAUMATOLOGY DEPARTMENT CHIEF
AT PITIÉ-SALPÊTRIÈRE HOSPITAL



"I develop innovative instruments for tomorrow's medical world. With the Dynamo (DYNAMIC Models) project, in collaboration with Professor Hampel, our teams are striving to create numerical modelling of brain evolution during Alzheimer's diseases, in hopes of creating a precise medical instrument, both predictive and personalized. Data comparison between patients and the model will allow teams to personalize the diagnosis and predict disease progression to put appropriate care in place as early as possible and implement tailored treatment. This innovative and interdisciplinary project was possible at ICM thanks to the constant interaction with clinicians made possible at the Institute."

STANLEY DURRLEMAN,
INRIA RESEARCH MATHEMATICIAN
AT ICM



"I am in charge of care management and development in the neurology department and am involved in the University Medical Center's three-fold mission: care, learning and training, and research. ICM-A-IHU helped train Nursing and Paramedical Research Committee members on how to develop a research project, allowing us to win a national call for projects with the Neurosex project. The project will implement nursing consultations in sexual health for patients with neurological diseases, and it motivated me to do a thesis supported financially by ICM-A-IHU. Thanks to ICM-A-IHU, the department developed a shared scientific culture and opens the door to innovation and research for hospital staff. It's a fantastic way to bring meaning back into what we do!"

SANDRINE LEFEBVRE,
SENIOR HEALTHCARE MANAGER
IN THE NERVOUS SYSTEM DISEASES
DEPARTMENT AT PITIÉ-SALPÊTRIÈRE
HOSPITAL



"I develop statistical analysis instruments and help users with the CENIR MEG-EEG platform. The unique side of ICM is that it puts equipment, infrastructure and staff under one roof, allowing us to pool resources, build collaborations, and help innovative projects come to light. I now work with everyone at ICM: researchers, doctors, engineers... on projects not only linked to the MEG-EEG but that also pertain to functional MRI, spectroscopy and TMS. ICM trusted me to organize a statistics course with Professor Hervé Abdi from Dallas University: it was a success, and I hope to get the opportunity again."

LYDIA YAHIA-CHÉRIF,
RESEARCH ENGINEER
ON THE MEG-EEG PLATFORM

WOMEN AT ICM

THE INSTITUTE WAS FOUNDED ON THE IDEA THAT FEMALE SCIENTISTS PLAY A FUNDAMENTAL ROLE IN RESEARCH AND OUR SOCIETY. A THINK TANK WAS IMPLEMENTED AT THE INSTITUTE TO FOCUS ON CURRENT AND FUTURE CONCERNS OF FEMALE RESEARCHERS WITHIN THE INSTITUTE.

The goal of the think tank, named XXInitiative and made up of women and men dedicated to promoting the role of women in science, is to come up with and execute effective action to:

- Encourage female scientists and their career
- Promote access to high-level scientific positions for women
- Drive governing bodies and scientific events towards gender parity



ICM BY THE NUMBERS

56 HOSPITAL PRACTITIONERS AND PARAMEDICAL STAFF

135 RESEARCHERS

55 POST-DOCTORAL RESEARCHERS

92 DOCTORAL RESEARCHERS

181 ENGINEERS AND TECHNICIANS

88 ADMINISTRATIVE STAFF

32 DIFFERENT COUNTRIES REPRESENTED

SO MUCH HAPPENING AT ICM

The AJITÉS, ICM Youth Organization and Associates, was founded in 2012.

It organizes all sorts of activities from yoga, salsa dancing, Science-Pizza, Happy Hours to practice for oral presentations and doctoral and post-doc workshops, an opportunity to develop interdisciplinary

research projects. The organization aims at developing communication, interaction and collaboration among ICM staff. It is frequently updated, bringing a strong internal motivation and forward drive to the Institute. For those constantly on the lookout for new projects and who enjoy

meeting new people, ICM is a unique opportunity to think differently, open up our approach and ways of working, and to innovate. Working at ICM means belonging to something greater: a community dedicated to Neuroscience.

GOVERNANCE FOCUSED ON EFFICIENCY AND FLEXIBILITY



ICM's governance is based on a strong partnership between the public and private sectors, as illustrated by its board members and governing bodies. They ensure that structures and resources properly match scientific goals. The Executive Committee implements monitoring to ensure efficient management is in place, as well as ongoing evaluation of work done by the teams and their results, to guarantee continued excellence. Through its Annual Report, ICM is dedicated to providing information on its mission and results for total transparency in its partnerships.

In March 2011, ICM signed, with academic partners AP-HP, CNRS, Inserm and UPMC, an agreement which governs the modalities of work in common of research teams under the direction of ICM general director. This agreement provides the creation of a Coordination Committee (which stem from the Executive Board of ICM), whose role is to make proposals to the Executive Board of ICM on the research strategy of the Institute.

In 2016, the Director of ICM was appointed General Director of the IHU-A-ICM to ensure both entities benefit from one single governing body as their social mission shares numerous traits, with a common roadmap.

The Board of Directors also approved the merger of both entities, planned for 2017.

THE BOARD OF DIRECTORS

The board of directors manages Institute affairs through its proceedings. It weighs in on strategic directions presented by the Chief Executive, adopts budgets and approves accounts.

The Foundation is governed by a board made up of fifteen members including:

- 5 founding college members;
- 3 members of the college of qualified persons;
- 4 ex officio members;
- 3 members of the college of friends of the foundation.

The college of founders includes not only the founders themselves, but also members selected by the founding college and renewed by it.

The college of qualified persons includes individuals chosen for their competency in the foundation's field.

The college of ex officio members includes representatives from AP-HP, CNRS, INSERM and Pierre et Marie Curie University.

The college of friends of the foundation is comprised of individuals appointed by the Circle of Friends of ICM.

With the exception of founding members, all board members are appointed for a three-year term with one third renewed annually. Their term can be renewed.

The bureau meets at least four times per year at the initiative of the President of the Foundation in order to:

- Make arrangements, acting on authority of the Board of Directors when applicable, to ensure the foundation runs smoothly between board meetings;
- Manage preparation and monitoring of decisions made by the board of directors.

BOARD OF DIRECTORS MEMBERS

Gérard SAILLANT
Professor of orthopedic and trauma surgery, President of ICM

Jean TODT
President of the FIA, Vice-President of ICM

COLLEGE OF FOUNDERS

Serge WEINBERG
Jean GLAVANY
Jean-Pierre MARTEL
Gérard SAILLANT
Jean TODT

COLLEGE OF QUALIFIED PERSONS

Pierre CORVOL
Collège de France
Richard FRACKOWIAK
École Polytechnique Fédérale de Lausanne
Elisabeth TOURNIER-LASERVE
Université Paris Diderot

COLLEGE OF EX OFFICIO MEMBERS

Bernard POULAIN
Representative of the National Center for Scientific Research (CNRS)
Thierry DAMERVAL
Representative of the National Health and Medical Research Institute (INSERM)
Bruno RIOU
Representative of Pierre et Marie Curie University (UPMC)
Ali FERHI
Representative of Assistance Publique - Hôpitaux de Paris (AP-HP)

COLLEGE OF FRIENDS OF THE FOUNDATION

Maurice LÉVY
Jean-Philippe HOTTINGUER
David de ROTHSCHILD

GOVERNMENT COMMISSIONER

Philippe RITTER

FOUNDING MEMBERS

Gérard SAILLANT,
Professor of orthopedic and trauma surgery, President of ICM

Jean TODT
President of the FIA, Vice-President of ICM

Yves AGID
Honorary Professor of neurology and neuroscience
Luc BESSON
Director

Louis CAMILLERI
President of Altria

Jean GLAVANY
Former Minister, Representative of the Hautes-Pyrénées
Maurice LÉVY

President of the Board of Publicis Group, Co-President of the Friends of ICM Committee
Olivier LYON-CAEN
Professor of neurology, former Director of the Nervous System Diseases department at Pitié-Salpêtrière University Medical Center

Jean-Pierre MARTEL
Lawyer,
Max MOSLEY

Former President of the FIA
Lindsay OWEN-JONES

Honorary President of L'Oréal, Honorary President of the Friends of ICM Committee

David de ROTHSCHILD
President of Rothschild & Cie bank,

Co-President of the Friends of ICM Committee

Michael SCHUMACHER
Formula 1 Pilot

Serge WEINBERG
President of Weinberg Capital Partners, ICM Treasurer

FRIENDS OF ICM

Lily SAFRA Honorary President, President of the philanthropic Edmond J. Safra Foundation

Gérard SAILLANT Professor of orthopedic surgery and traumatology, President of ICM

Jean TODT President of the FIA, Vice-President of ICM
Lindsay OWEN-JONES Honorary President of L'Oréal, Honorary President of the Friends of ICM Committee
Maurice LÉVY President of the Board of Directors of Publicis Group, Co-President of the Friends of ICM Committee

David de ROTHSCHILD President of the Rothschild & Cie Bank, Co-President of the Friends of ICM Committee

Jean-Pierre MARTEL Lawyer

Serge WEINBERG President of Weinberg Capital Partners and ICM Treasurer

AUDIT COMMITTEE

Serge WEINBERG

Audit Committee President

Thierry DAMERVAL
Deputy Chief Executive of INSERM

Jean GLAVANY
Former Minister, Representative of the Hautes-Pyrénées

Jean-Pierre MARTEL
Lawyer, Founding Member of ICM

COORDINATION OF FOUNDATION AND PUBLIC PARTNER RELATIONSHIPS COMMITTEE

Gérard SAILLANT
Professor of orthopedic and trauma surgery, President of ICM

Ali FERHI
Representative of AP-HP

Bernard POULAIN
Representative of CNRS

Thierry DAMERVAL
Representative of l'INSERM

Bruno RIOU
Representative of UPMC

AMBASSADORS

Jean RENO

Acteur

Michèle YEOH

Actrice

THE SCIENTIFIC ADVISORY BOARD

The International Scientific Advisory Board (SAB) assists the Board of Directors or Chief Executive on strategic directions, programs, or scientific strategies for the Institute. Its members are top international neuroscience experts. Every five years, ICM is assessed, as a Mixed Research Unit (UMR), on the quality of its research, its organization, strategy, and five-year scientific plan.

Research projects are assessed by the SAB, with the mission of advising the Institute and helping it define its overall approach. Following a period of discussions, the SAB provides input that is taken into account to build the file for assessment by the Committee for Assessment of Research and Higher Education (HCERES).

"Our challenge is to create an Institute for Excellence in Research that is an international leader in Neuroscience".

Professor Alexis Brice,
Chief Executive of ICM

Michael Shelanski -
President

Dimitri Kullman

Gabor Tamas

Peter Brown

Brad Hyman

Stephen Hauser

Bill Richardson

Helen Mayberg

Christian Buchel

Arnold Kriegstein

Masud Husain

Michael Heneka

MISSION

UNDERSTANDING THE NERVOUS SYSTEM IMPLIES HAVING A HUMAN SKILL SET AND THE INSTRUMENTAL AND ORGANIZATIONAL CAPACITY TO OBTAIN RELEVANT DATA FOR EACH LEVEL OF RESEARCH, TO ANALYZE FUNDAMENTAL DATA AND TO CORRELATE AND INTEGRATE IT TO GIVE RISE TO A COHERENT VISION, FROM THE MOLECULAR AND CELLULAR LEVEL UP TO COGNITIVE AND BEHAVIORAL LEVELS.



A key player at the heart of 21st century challenges *p.32*

What does it mean **to do research** today? *p.34*

Cutting-edge research

Research programs *p.36*

Research teams *p.40*

Overview and publication examples *p.44*

Synergy *p.50*

Awards and distinctions *p.52*

Teaching and **training** *p.54*

National and **international** collaboration *p.56*

Clinical research

Center for Clinical Investigation *p.58*

Nervous System Diseases Center *p.60*

Knowledge sharing & **innovation**

Research & Technology Development Office *p.62*

Living Lab & Findmed *p.64*

iPEPS-ICM incubator *p.66*

SUPPORT **OUR MISSION**

State-of-the-art technological platforms *p.70*

A KEY PLAYER AT THE HEART OF 21ST CENTURY CHALLENGES

NEARLY ONE BILLION INDIVIDUALS WORLDWIDE ARE AFFECTED BY NEUROLOGICAL OR PSYCHIATRIC ILLNESS, AND 80% OF THESE INDIVIDUALS DO NOT BENEFIT FROM APPROPRIATE OR ADEQUATE TREATMENT. THE CHALLENGE IS HUGE. FOR YEARS, THE INDUSTRY HAS FACED INCREASING FAILURE RATES IN INNOVATIVE DRUG DEVELOPMENT: 15% OF CANDIDATE DRUGS THAT UNDERGO CLINICAL TESTING ARE PUT ON THE MARKET, YET THIS FIGURE DROPS TO 7% FOR THE NERVOUS SYSTEM. ADDITIONALLY, IN THIS EXTREMELY COMPLEX FIELD OVER 12 YEARS ARE NEEDED FOR A DRUG TO BE READY VERSUS, FOR EXAMPLE, 6.5 YEARS IN THE FIELD OF CARDIOVASCULAR ILLNESS.

WHY IS IT TAKING SO LONG TO DEVELOP TREATMENT FOR NERVOUS SYSTEM DISEASES?

There are several reasons. First of all, the major neurodegenerative diseases share a late appearance of clinical symptoms. For example, the first signs of Parkinson's disease appear when over 80% of dopaminergic neurons in the substantia nigra have already been destroyed. In the same manner, the brain can be flooded with amyloid plaques without a patient showing any clinical symptoms of Alzheimer's yet. Treatment is administered late in the disease, so its efficacy is limited due to irreversible damage already experienced by the brain. One of the most promising approaches to reach very early detection - at the infraclinical stage - of the disease consists in multimodal biomarker research on individuals with a high risk of developing the disease. These high-risk individuals are those related to patients with a genetic form of the disease.

A second reason lies in the fact that the design itself of candidate drugs to treat nervous system diseases is complicated by the "Great Wall of China" that is the blood-brain barrier, which prevents drugs from passing through. The chemical and protein engineering required to ensure that a specific therapeutic molecule reaches the appropriate target cell is colossal. The third major obstacle in developing drugs that work is the relevance of new targets. Action directed against a certain cellular target can have completely antagonistic effects from one area of the brain to another, increasing the risk of side effects. Finally, lack of knowledge surrounding disease physiopathology and the inexistence of satisfactory preclinical modelling leads to dramatic failures in drug development.



"In Europe, 1 in 8 individuals is affected by nervous system illness"


ICM: A HIGH-LEVEL INSTITUTE FACED WITH EVEN HIGHER STAKES

ICM's defining strength is its ability to take into account the whole healthcare process rather than drugs alone. This approach brings together research, platform and expert support, startup technology and national and international network involvement.

Moreover, success - in particular that of the Center for Clinical Investigation, housed in ICM - was obtained through the creation of a collaborative environment between researchers, doctors and patients. Industry partnerships between the public and private sector at ICM helped accelerate and turn discoveries into practical treatment solutions for clinical use, while lowering academic

constraints often found in research. The Nervous System Diseases department opens its doors to 80,000 patients every year, who have access to the latest treatment breakthroughs and are active participants in research. Positioned at the crossroads of various fields, ICM asserts a global approach to illness, and is lowering the barriers separating pharmacy, technology and humanities to design integrated healthcare that starts with prevention, leading up to management of disabilities, using technology as a dedicated instrument. This strategy is implemented with the development of a startup accelerator, currently hosting 16 businesses, the new living lab

dedicated to tech solutions, and the neuroinformatics project that aims at implementing instruments to encourage more predictive and quantitative medicine when it comes to diagnosis, prognosis and therapy. Finally, the creation of a hospital living lab helps accelerate development of shared early-stage projects with "medtech" companies as well as business focused on telemedical services. One of the main goals is to increase the number of French startups in the field by dedicating the necessary resources to designing functional prototypes approved for patient use.




BEING A RESEARCHER TODAY

Researchers today are women and men who do it all: to recruiting top talent, building a multidisciplinary and multicultural team and securing financing. Being a researcher today means solving scientific problems, sharing results with scientists and the general public while keeping an eye on research elsewhere around the world. Being a researcher is motivating, but also very demanding!

For researchers and experts, ICM is the ideal place to come up with new ideas, nurture broader reflection, and build projects. The diversity of talent and unique interactions at the Institute enrich the everyday work of research team. To work on a project together, potential partners need to be available and the timing has to be just right. Building a suitable environment is of prime importance.

Scientific research is a long-term endeavor and requires financial, human, technological and environmental investment. Some research that may go under the radar could possibly reveal its full potential on the long term.



RESEARCH PROGRAMS AT THE HEART OF HEALTHCARE

4 RESEARCH PRIORITIES

FOCUS 1 : UNDERSTANDING THE BRAIN'S MAJOR FUNCTIONS

BEHAVIOR AND COGNITION

Perception, language, motivation, reasoning, emotions, creativity, memory, attention, and conscience form the basis of human behavior. To describe and understand the brain's major functions, ICM teams rely on experimental methods from the most subtle clinical analysis, electrophysiological testing, to brain imaging. Thanks to this approach, Institute researchers study the relationship between genetics, brain function, and behavior in healthy individuals as well as patients with neuropsychiatric disorders (depression, OCD, trauma, apathy, dementia...) in order to identify new markers of behavior and cognition both normal and abnormal. The goal is to offer diagnostic tools and treatments tailored to each patient.

FOCUS 2 : UNDERSTANDING NEURAL INTERACTION




NEUROPHYSIOLOGY

Nerve impulse transmission in the various neural networks is the basis of nervous system activity. It relies on excitability, conduction, and transmission of the nerve impulse generated by each neuron and on network plasticity. Brain and spinal cord neurophysiology, from single cells to the whole network, help understand the principles through which neural activity leads to specific functions that induce normal or abnormal behavior. The study of neural networks is a foundational aspect of therapeutic research for various illnesses: epilepsy, trauma, neurodegenerative illnesses, psychiatric disorders. The goal, on the one hand, is to reach a better understanding of neural and network physiology to improve disease treatment. On the other hand, it is to better understand the role played by neural activity during development and repair in neurodegenerative illnesses. Surface electrophysiology (transcranial magnetic stimulation) and intracerebral electrophysiology (deep brain stimulation) in humans are one of ICM's greatest strengths. They make it possible to treat certain illnesses such as Parkinson's disease, OCD, essential tremor, to encourage rehabilitation after a stroke and to monitor severe forms of certain diseases such as epilepsy.

FOCUS 3 : DECRYPT UNDERLYING CELLULAR AND MOLECULAR MECHANISMS OF BRAIN FUNCTION IN NORMAL AND PATHOLOGICAL CONDITIONS

CELLULAR AND MOLECULAR BIOLOGY

ICM teams working in molecular and cellular neuroscience are involved in a collaborative effort to understand normal brain and spinal cord development as well as the reasons behind dysfunction in the case of aging and neurological illness (neurodegenerative diseases, multiple sclerosis, epilepsy, brain tumors). ICM's strategy is focused on evaluating the influence of genetics, dissecting the molecular process behind intracellular signalling, understanding the role of various cell types and the complex cell interactions in normal and pathological states. Understanding the molecular and cellular basis of nervous system disorders is key to figuring out what the underlying mechanisms of disease are and to developing new diagnostic and treatment approaches.



FOCUS 4 : TRANSFERRING KNOWLEDGE TO IMPROVE PREVENTION AND TREATMENT OF NERVOUS SYSTEM DISEASES

CLINICAL AND TRANSLATIONAL RESEARCH

Clinical and translational research dedicated to neurological and psychiatric illnesses aims at developing innovative therapies for nervous system diseases. By bringing patients, doctors and researchers together in one place, ICM's goal is to encourage rapid development of treatments for nervous system damage in order to pass it along to patients as early as possible: from treatment identification on simple models in a laboratory setting to clinical trials on patients at the Center for Clinical Investigation at ICM. ICM's strength also lies in the iPEPS-ICM incubator that creates a pathway between research and resulting real-life medical applications. The implementation of a living lab (UCIL) where patients, developers and healthcare professionals meet to generate ideas and apply them is the ultimate link in the chain created to meet patient needs. The goal of this research is to develop instruments that will help with early disease diagnosis and to explore innovative therapeutic options. Therapy means drugs to fight the disease and slow its progress, but it also means medical techniques such as deep brain stimulation to help patient well-being or digital solutions that improve patient independence like smartphone apps, connected devices or therapeutic games.

26 TEAMS TACKLING THE NERVOUS SYSTEM LESIONS IN 2016

THE ICM'S 26 RESEARCH TEAMS WORK HAND IN HAND TO UNDERSTAND NORMAL AND PATHOLOGICAL BRAIN FUNCTIONS, TO DIAGNOSE NEUROLOGICAL ILLNESS AS EARLY AS POSSIBLE AND TO IDENTIFY POSSIBLE TREATMENTS.

CELLULAR PHYSIOLOGY OF CORTICAL MICROCIRCUITS

Team leader(s) : Alberto BACCI

Principal investigators
Alberto BACCI
Xavier DREVELLE

GENEROUS SUPPORT GRANTED BY :
ANR - Agence nationale de recherche DGCS - Ministère de l'Égalité des Territoires et du Logement
ENP -Ecole des neurosciences Paris Ile de France
FRM - Fondation pour la Recherche Médicale

CELLULAR AND MOLECULAR APPROACHES FOR MYELIN REPAIR

Team leader(s)
Anne BARON VAN EVERCOOREN
Brahim NAIT OUMESMAR

Principal investigators
Anne BARON
Brahim NAIT OUMESMAR
Lamia BOUSLAMA
Violetta ZUJOVIC

GENEROUS SUPPORT GRANTED BY :
AFM - Association Française contre les Myopathies
ANR - Agence nationale de recherche ARSEP - Aide à la Recherche sur la Sclérose en Plaques
ELA research foundation
ENP -Ecole des neurosciences Paris Ile de France
Fondation Jérôme Lejeune
FRC - FEDERATION POUR LA RECHERCHE SUR LE CERVEAU
NMSS - national Multiple Sclerosis Society
OCIRP
UPMC

PICNIC LAB: PHYSIOLOGICAL INVESTIGATIONS OF CLINICALLY NORMAL AND IMPAIRED COGNITION

Team leader(s)
Paolo BARTOLOMEO
Laurent COHEN
Lionel NACCACHE

Principal investigators
Paolo BARTOLOMEO
Laurent COHEN
Lionel NACCACHE
Jacobo SITT

GENEROUS SUPPORT GRANTED BY :
ANR - Agence nationale de recherche
CEE - European Commission
ENP -Ecole des neurosciences Paris Ile de France
Fondation Voir et Entendre
FRM - Fondation pour la recherche médicale
LesHanot Haim Foundation
McDonnell Foundation
Sylvain Héfès

GENETICS AND PHYSIOPATHOLOGY OF EPILEPSY

Team leader(s)
Stéphanie BAULAC
Eric LEGUERN

Principal investigators
Stephanie BAULAC
Eric LEGUERN
Christel DEPIENNE
Sarah WECKHUYSSEN

GENEROUS SUPPORT GRANTED BY :
Ambassade de France au japon
ANR - Agence nationale de recherche
APHP
CEE - European Commission
FDF - Fondation de France
FMR - Fondation Maladies Rares (ex GIS)
FRC - FEDERATION POUR LA RECHERCHE SUR LE CERVEAU

ALS : CAUSES AND MECHANISMS OF MOTOR NEURON DEGENERATION

Team leader(s)
Séverine BOILLÉE

Principal investigators
Severine BOILLÉE
Delphine BOHL
Christian LOBSIGER
Stephanie MILLECAMPES
Danielle SEILHEAN
François SALACHAS
Vincent MEININGER

GENEROUS SUPPORT GRANTED BY :
ACE - Association pour l'étude de la culture d'embryon
AFM - Association Française contre les Myopathies
ALS association
ANR - Agence nationale de recherche
ANSES - Agence Nationale de Sécurité Sanitaire de l'Alimentation de l'Environnement et du travail
ARMC - Aide à la recherche des Maladies du Cerveau
ARSLA - Association pour la Recherche sur la Sclérose Latérale Amyotrophique et autres maladies du motoneurone
Fondation Thierry Latran
Institut Pasteur
Medday
Amélie FAYET
Edith DEBOUDE

MOLECULAR BASIS, PHYSIOPATHOLOGY AND TREATMENT OF NEURODEGENERATIVE DISEASES

Team leader(s)
Alexis BRICE

Principal investigators
Alexis BRICE
Olga CORTI
Jean-Christophe CORVOL
Frederic DARIOS
Christel DEPIENNE

Alexandra DURR
Isabelle LEBER
Suzanne LESAGE
Fanny MOCHEL
Annie SITTLER
Giovanni STEVANIN
Hamid ELHACHIMI
Morwena LATOUCHE
Claire PUJOL
Caroline NAVA

GENEROUS SUPPORT GRANTED BY :
ADRMGNP - Association pour le Développement de la Recherche sur les Maladies Génétiques Neurologiques et Psychiatriques
AFH - Don
AHF - Association Huntington France
ANR - Agence nationale de recherche
ANSM - Agence Nationale de Sécurité du Médicament et des Produits de Santé
APHP
ASL - Association Strümpell-Lorrain
BOLLORE
CEE - European Commission
Centre Hospitalo-Universitaire Régional de Lille
CHDI Foundation
CSC- Association Connaître les Syndromes Cérébelleux
DIM Cerveau et Pensée Manifestations Scientifiques
Elisabeth Badinter
ENP -Ecole des neurosciences Paris Ile de France
F-CRIN
FDF - Fondation de France
FMR - Fondation Maladies Rares (ex GIS)
Fondation Carlo Besta
Fondation Edmond J. Safra
Fondation Jacques et Gloria Gossweiler
Fondazione Istituto Neurologico Carlo Besta
France Parkinson
FRM - Fondation pour la recherche médicale
HUNTINGTON ESPOIR OUEST
INSERM -COSSEC
ULM - University Hospital of ULM
VERUM FONDATION
Ultragenyx Pharmaceutical Inc.

EXCITABILITY AND DYNAMICS OF NEURONAL ASSEMBLIES

Team leader(s)
Stéphane CHARPIER

Principal investigators
Stéphane CHARPIER
Michel LE VAN QUYEN
Severine MAHON
Vincent NAVARRO
Mario CHAVEZ

GENEROUS SUPPORT GRANTED BY :
ANR - Agence nationale de recherche
FRC - Fondation pour la Recherche sur le Cerveau
Institut Universitaire d'Ingénierie pour la Santé (IUIS)
OCIRP

ARAMIS: ALGORITHMS, MODELS AND METHODS FOR IMAGES AND SIGNALS OF THE HUMAN BRAIN

Team leader(s)
Olivier COLLIOT
Didier DORMONT

Principal investigators
Olivier COLLIOT
Didier DORMONT
Stanley DURLEMANN
DE VICO FALLANI
Fabrizio DE VICO FALLANI
Marie CHUPIN
Anne BERTRAND
Damien GALANO
Dominique HASBOUN
Sophie DUPONT
Yves SAMSON

GENEROUS SUPPORT GRANTED BY :
ANR - Agence nationale de recherche
APHP
CEE - European Commission
Tous les donateurs du projet DYNAMO

FRONTLAB: FRONTAL SYSTEMS, FUNCTIONS AND DYSFUNCTIONS

Team leader(s)
Bruno DUBOIS
Richard LEVY

Principal investigators
Bruno DUBOIS
Richard LEVY
Benedicte BATRANCOURT
Raffaella MIGLIACCIO
Michel THIEBAUT
Antoni VALEROCABRE
Emmanuelle VOLLE
Harald HAMPEL
Marc TEICHMAN

GENEROUS SUPPORT GRANTED BY :
Association PSP France
ANR - Agence nationale de recherche
APHP
CEE - European Commission
DIM Cerveau et Pensée Petits et Moyens Equipements
FRM - Fondation pour la recherche médicale
NIH - National Institutes of Health
Edouard et Martine de ROYERE

GEN-PHYS: NEUROGENETICS AND PHYSIOLOGY

Team leader(s)
Bertrand FONTAINE
Sophie NICOLE

Principal investigators
Bertrand FONTAINE
Sophie NICOLE
Cécile DELARASSE
Mohamed EL BEHI
Isabelle REBEIX
Laure STROCHLIC

GENEROUS SUPPORT GRANTED BY :
AFHA - Association Française de l'Hémiplégie Alternante
AFM - Association Française contre les Myopathies
ARN - Association pour la recherche sur les Nicotianées
ARSEP - Aide à la recherche sur la sclérose en plaques
DIM Cerveau et Pensée Manifestations Scientifiques
FMR - Fondation Maladies Rares (ex GIS)
Fondation de l'Avenir
Université Claude Bernard Lyon 1
GeNeuro SA

SOCIAL AND AFFECTIVE NEUROSCIENCE

Team leader(s)
Nathalie GEORGE
Philippe FOSSATI

Principal investigators
Nathalie GEORGE
Philippe FOSSATI
Stephanie DUBAL
Bruno MILLET

GENEROUS SUPPORT GRANTED BY :
ANR - Agence nationale de recherche
DIM Cerveau et Pensée Petits et Moyens Equipements
Fondation des Geules Cassées
Fondation Pierre Deniker
FRM - Fondation pour la recherche médicale
Purdue University North Central

ALZHEIMER'S DISEASE, PRION DISEASES

Team leader(s)
Stéphane HAIK
Marie-Claude POTIER

Principal investigators
Stephane HAIK
Marie-Claude POTIER
Benoit DELATOUR
Nicolas BIZAT
Charles DUYCKAERTS
Stéphane EPELBAUM

Serge MARTY
Jean-Philippe BRANDEL

GENEROUS SUPPORT GRANTED BY :
ANR - Agence nationale de recherche
CJD Foundation
France Alzheimer
GIS - IBISA
Institut Pasteur
InVs - Institut de veille sanitaire
LECMA - Ligue Européenne
contre la Maladie Alzheimer
LFB Biomédicaments
Les Laboratoires Servier
Sanofi-Aventis Recherche
et Développement
Medday

NEURAL DEVELOPMENT

Team leader(s)
Bassem HASSAN

Principal investigators
Bassem HASSAN

GENEROUS SUPPORT GRANTED BY :
The Paul Allen Family Foundation

EXPERIMENTAL THERAPY IN PARKINSON'S DISEASE

Team leader(s)
Etienne HIRSCH

Principal investigators
Etienne HIRSCH
Stephane HUNOT
Patrick MICHEL
Marie-Laure WELTER
David GRABLI
Rita RAISMAN
Annie LANNUZEL
Chantal FRANCOIS

GENEROUS SUPPORT GRANTED BY :
PSP
ANR - Agence nationale de recherche
BPI France financement
CEE - European Commission
CR IDF
FRC - FEDERATION POUR
LA RECHERCHE SUR LE CERVEAU
FRM - Fondation pour la Recherche
Médicale
IETF - International Essential Tremor
Foundation

MJFOX - THE MICHAEL J FOX
FOUNDATION
Air Liquide Santé International

MOLECULAR AND CELLULAR MECHANISMS OF GLIOMA GENESIS

Team leader(s)
Emmanuelle HUILLARD

Principal investigators
Emmanuelle HUILLARD
Isabelle LE ROUX

GENEROUS SUPPORT GRANTED BY :
Cancéropôle Ile-de-France
CEE - European Commission
INSERM - ATIP AVENIR
La Ligue nationale contre le Cancer

TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS: FROM GENETICS TO ZEBRAFISH

Team leader(s)
Edor KABASHI

Principal investigators
Edor KABASHI
Sorana CIURA

GENEROUS SUPPORT GRANTED BY :
AFM - Association Française contre
les Myopathies
ANR - Agence nationale de recherche
CEE - European Commission
FRC - Fédération pour la Recherche
sur le Cerveau
FRM - Fondation pour la recherche
médicale
Anavex Life Sciences Corp.

EXPERIMENTAL NEUROSURGERY

Team leader(s)
Brian LAU

Principal investigators
Brian LAU
Carine KARACHI

GENEROUS SUPPORT GRANTED BY :
ANR - Agence nationale de recherche
CEE - European Commission
France Parkinson
Simons Foundation
Jean-Louis DUFLOUX

ABNORMAL MOVEMENTS AND BASAL GANGLIA: PHYSIOPATHOLOGY AND EXPERIMENTAL THERAPY

Team leader(s)
Stéphane LEHERICY
Marie VIDAILHET

Principal investigators
Marie VIDAILHET
Stephane LEHERICY
Andreas HARTMANN
Pierre POUGET
Charlotte ROSSO
Emmanuel ROZE
Isabelle ARNULF
Bertrand DEGOS
Sabine MEUNIER
Alexandra PETIET
Sophie RIVAUD-PECHOUX

GENEROUS SUPPORT GRANTED BY :
AFGST / FRM - Fondation pour la
recherche médicale
AFHA - Association Française
de l'Hémiplégie Alternante
ANR - Agence nationale de recherche
APHP
APTES - Association des personnes
concernées par le tremblement essentiel
Campus France - Campus Prestige
ENS - Ecole Normale Supérieur
Fondation BETTENCOURT SCHUELLER
Fondation NRJ
Fonds PATRICK DE BROU DE LAURIERE
France Parkinson
INSERM
Institut de Recherche sur la Moelle
Epinière et l'Encéphale (IRME)
MDSD France
PSP
Quintiles Benefit France
Fondation EDF
Fonds de dotation PIERRE BERGE
Fondation AREVA
Edouard et Martine de ROYERE
ORKYN'
Institut de recherches internationales
Servier

MECHANISMS OF MYELINATION AND REMYELINATION IN THE CNS

Team leader(s)
Catherine LUBETZKI
Bruno STANKOFF

Principal investigators
Catherine LUBETZKI
Bruno STANKOFF

Marc DAVENNE
Anne DESMAZIERES
Nathalie SOL-FOULON

GENEROUS SUPPORT GRANTED BY :
ANR - Agence nationale de recherche
ARSEP - Aide à la Recherche sur la
Sclérose en Plaques
FDF - Fondation de France
FRM - Fondation pour la recherche
médicale
INSERM - interface
MSIF - Multiple Sclerosis International
Federation
NMSS - national Multiple Sclerosis
Society
Fondation MARIE-ANGE BOUVET
LABRUYERE

BEHAVIOR, EMOTION, AND BASAL GANGLIA

Team leader(s)
Luc MALLET
Jérôme YELNIK

Principal investigators
Luc MALLET
Jérôme YELNIK
Eric BURGUIERE
Karim NDIAYE

GENEROUS SUPPORT GRANTED BY :
ANR - Agence nationale de recherche
ARS Ile de France
Christian POQUET
Fondation de l'avenir
Fondation Fondamental
FRM - Fondation pour la recherche
médicale
Fondation Philippe et Maria Halphen

CORTEX AND EPILEPSY

Team leader(s)
Richard MILES

Principal investigators
Richard MILES
Desdemona FRICKER

GENEROUS SUPPORT GRANTED BY :
CEE - European Commission
ANR - Agence nationale de recherche

MOTIVATION, CERVEAU ET COMPORTEMENT

Team leader(s)
Mathias PESSIGLIONE

Sébastien BOURET
Jean DAUNIZEAU

Principal investigators
Mathias PESSIGLIONE
Sebastien BOURET
Jean DAUNIZEAU

GENEROUS SUPPORT GRANTED BY :
Campus France - Campus Prestige
CEE - European Commission
DIM Cerveau et Pensée Manifestations
Scientifiques
ENP -Ecole des neurosciences
Paris Ile de France
FRM - Fondation pour la Recherche
Médicale
Ministère Français des Affaires
Etrangères
Claude FELIX

BIOTECHNOLOGY AND BIOTHERAPY

Team leader(s)
Philippe RAVASSARD

Principal investigators
Philippe RAVASSARD
Rolando MELONI
Helene CHEVAL

GENEROUS SUPPORT GRANTED BY :
CEE - European Commission
FMR - Fondation Maladies Rares
(ex GIS)
Fondation E. J. SAFRA
Les Laboratoires Servier

EXPERIMENTAL NEURO-ONCOLOGY

Team leader(s)
Marc SANSON

Principal investigators
Marc SANSON
Jean-Yves DELATTRE
Michel KALAMARIDES
Khe HOANG-XUAN
Ahmed IDBAIH

GENEROUS SUPPORT GRANTED BY :
APHP
Cancéropôle Ile-de-France
Fondation ARC pour la recherche
sur le cancer
Institut national du cancer (INCa)
La Ligue nationale contre le Cancer
Plan Cancer
Transgene
Gecko Biomedical
Eli Lilly and Company

OLIGODENDROCYTE DEVELOPMENT AND NEUROVASCULAR INTERACTIONS

Team leader(s)
Jean-Leon THOMAS (Boris ZALC)

Principal investigators
Jean-Leon THOMAS
Boris ZALC
Charles CALVO
Carlos PARRAS
Michel MALLAT

GENEROUS SUPPORT GRANTED BY :
ANR - Agence nationale de recherche
ANSES - Agence Nationale de Sécurité
Sanitaire de l'Alimentaion de
l'Environnement et du travail
ARSEP - Aide à la recherche
sur la sclérose en plaques
NMSS - national Multiple Sclerosis
Society

PROBING DYNAMIC SENSORY-MOTOR INTEGRATION IN SPINAL CIRCUITS

Team leader(s)
Claire WYART

Principal investigators
Claire WYART
Pierre-Luc BARDET
Hugues PASCAL MOUSSELARD

GENEROUS SUPPORT GRANTED BY :
CEE - European Commission
EMBO
ENP -Ecole des neurosciences
Paris Ile de France
FRM - Fondation pour la recherche
médicale
Fondation MICHELIN
HFSP0- The Human Frontier Science
Program Organization
RIF - Région Ile de France
RTRA - ENP

2016, A YEAR OF BREAKTHROUGHS

ON THE RESEARCH SIDE

ALZHEIMER'S

Hope for early patient care through discovery of brain lesions due to the illness 20 years prior to onset.

By Harald Hampel part of the team led by Bruno Dubois

Jansen W.J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. *Jama, The Journal of the American Medical Association*, 19 mai 2015; 313(19):1924-38

PARKINSON'S

Development of a new molecule involved in the disease.

From the team led by Etienne Hirsch

New 6-Aminoquinoxaline Derivatives with Neuroprotective Effect on Dopaminergic Neurons in Cellular and Animal Parkinson Disease Models. Gael Le Douaron, Laurent Ferrié, Julia E. Sepulveda-Díaz, Majid Amar, Abha Harfouche, Blandine Séon-Méniel, Rita Raisman-Vozari, Patrick P. Michel & Bruno Figadère. *J. Med. Chem.* 14 juillet 2016, 59(13):6169-86

AMYOTROPHIC LATERAL SCLEROSIS, ALS

Discovery of a new mechanism.

From the team led by Edor Kabashi

THE MOST PREVALENT GENETIC CAUSE OF ALS-FTD, C9ORF72 SYNERGIZES THE TOXICITY OF ATXN2 INTERMEDIATE POLYGLUTAMINE REPEATS THROUGH THE AUTOPHAGY PATHWAY. Ciura S, Sellier C, Campanari ML, Charlet-Berguerand N, Kabashi E. *Autophagy*. 2016 Aug. Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to induce motor neuron dysfunction and cell death. Sellier C, Campanari ML, Julie Corbier C, Gaucherot A, Kolb-Cheynel I, Oulad-Abdelghani M, Ruffenach F, Page A, Ciura S, Kabashi E, Charlet-Berguerand N. *EMBO J.* 2016 Jun.

ALS

Highlighting similarities between ALS and hereditary spastic paraplegia to allow clinicians to improve diagnosis.

From the team led by Alexis Brice

Motor neuron degeneration in spastic paraplegia 11 mimics amyotrophic lateral sclerosis lesions. Denora PS, Smets K, Zolfanelli F, Ceuterick-de Groote C, Casali C, Deconinck T, Sieben A, Gonzales M, Zuchner S, Darios F, Peeters D, Brice A, Malandrini A, De Jonghe P, Santorelli FM, Stevanin G, Martin JJ, El Hachimi KH. *Brain*. 2016 Jun;139(Pt 6):1723-34.

EPILEPSY

Proof in "real time" of a process involved in the interruption of conscious perception during absence seizures.

From the team led by Stéphane Charpier

Integrative properties and transfer function of cortical neurons initiating absence seizures in a rat genetic model. Williams Mark S., Altwegg-Boussac Tristan, Chavez Mario, Lecas Sarah, Mahon Séverine and Charpier Stéphane. *The Journal of Physiology*, June 17, 2016, 594(18):1-19

COGNITION

The more tired we feel due to intense work, the more impulsive we get during financial decision-making.

Neural mechanisms underlying the impact of daylong cognitive work on economic decisions.

Bastien Blain, Guillaume Hollard, and Mathias Pessiglione. *PNAS*, 2016.

BRAIN ORGANIZATION

Decoding the frontal lobe's architectural organization.

By Michel Thiebaut de Schotten from the team led by Richard Lévy and Bruno Dubois

Rostro-caudal architecture of the frontal lobes in humans. Michel Thiebaut de Schotten, Marika Urbanski, Benedicte Batrancourt, Richard Lévy, Bruno Dubois, Leonardo Cerliani, Emmanuelle Volle. *Cerebral Cortex* (2016).

BRAIN DEVELOPMENT

Discovery of a new process.

From the team led by Bassem Hassan

Post-translational Control of the Temporal Dynamics of Transcription Factor Activity Regulates Neurogenesis. *Cell*, Xiao-Jiang Quan et al. 28 janvier 2016, 164(3): 460-75.

RARE DISEASES

Highlighting the role of protein calpain 1 in ataxia, its neuroprotective activity and key role in brain development and neuroplasticity.

Defects in the CAPN1 gene result in alterations in cerebellar development and in cerebellar ataxia in mice and humans. Yubin Wang et al., Cell Reports, 28 juin 2016, 16 (1): 79-91.

GILLES DE LA TOURETTE SYNDROME

Decoding the mechanisms leading to tic appearance and persistence.

From the team led by Marie Vidailhet and Stéphane Lehericy

Enhanced habit formation in Gilles de la Tourette syndrome. Delorme C, Salvador A, Valabrègue R, Roze E, Palminteri S, Vidailhet M, de Wit S, Robbins T, Hartmann A, Worbe Y. Brain. 2016 Feb;139(Pt 2):605-15.

SPINAL CORD TRAUMA

Renewed hope with the identification of new movement-regulating neurons.

From the team led by Claire Wyart


CSF-contacting neurons regulate locomotion by relaying mechanical stimuli to spinal circuits. Urs Lucas Böhm et al. Nat Commun. Nature Communication, 2016 Mar 7

MEMORY

Slow-wave sleep may play a part in memory consolidation when the brain replays what it experienced the previous day.

From the team led by Stéphane Charpier

High-frequency oscillations [...] during the wake-sleep cycle. Le Van Quyen M, Muller LE, Telenczuk B, Halgren E, Cash S, Hatsopoulos NG, Dehghani N, Destexhe A. Proc Natl Acad Sci U S A. 2016 Aug 16.



ON THE CLINICAL SIDE

ALZHEIMER'S

An imaging study coordinated by Marie Sarazin, is the first to highlight the early protective role of the brain's immune cells

Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging. Hamelin L, Lagarde J, Dorothée G, Leroy C, Labit M, Comley RA, de Souza LC, Corne H, Dauphinot L, Bertoux M, Dubois B, Gervais P, Colliot O, Potier MC, Bottlaender M, Sarazin M; Clinical IMABio3 team. Brain. 2016 Apr; 139(Pt 4):1252-64.

PARKINSON'S

Discovery of new gene VPS13C in an early form of the disease that may support implementation of a diagnostic instrument

from the team led by Alexis Brice

Suzanne Lesage et al., Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy, American Journal of Human Genetics, Mars 2016, 98(3): 500-513.

PARKINSON'S

Relationship between the brain stem and cardiac disorders highlighted thanks to cutting-edge imaging.

From the team led by Stéphane Lehericy and Marie Vidailhet

Medulla oblongata damage and cardiac autonomic dysfunction in Parkinson disease. Pyatigorskaya N, Mongin M, Valabregue R, Yahia-Cherif L, Ewencyk C, Poupon C, Debellemaniere E, Vidailhet M, Arnulf I, Lehericy S. Neurology. 2016 Dec 13;87(24):2540-2545.

PARKINSON'S

Markers identified to monitor and predict disease progression.

From the team led by Marie Vidailhet and Stéphane Lehericy


Ehrminger M. et al. The coeruleus/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder, Brain, avril 2016 ; 139 (4):1180-8

MULTIPLE SCLEROSIS

Cutting-edge technique developed to measure disease progression that would allow tailored treatment for each patient.

From Benedetta Bodini part of the team led by Bruno Stankoff and Catherine Lubetzki

Dynamic imaging of individual remyelination professoriles in multiple sclerosis. Bodini B, Veronese M, García-Lorenzo D, Battaglini M, Poirion E, Chardain A, Freeman L, Louapre C, Tchikviladze M, Papeix C, Dollé F, Zalc B, Lubetzki C, Bottlaender M, Turkheimer F, Stankoff B. Ann Neurol. 2016 Feb; 77(2):253-63. Bodini B. et al, Benzothiazole and stilbene derivatives as promising PET myelin radiotracers for multiple sclerosis, Annals of Neurology, 21 avril 2016.



TUMORS

Hope for tailored treatment of a certain type of cancer with glioblastomas that target oncogene MDM2.

From the team led by Marc Sanson

Verreault M. et al. Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2 amplified and TP53 wild-type glioblastomas. Clin Cancer Res. Mars 2016, 22(5) : 1185-96

EPILEPSY

New drug to treat focal seizures.

From Michel Baulac in the team led by Stéphanie Baulac and Eric Leguern

Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Baulac M, Rosenow F, Toledo M, Terada K, Li T, De Backer M, Werhahn KJ, Brock M. Lancet Neurol. 2017 Jan;16(1):43-54.

DOWN SYNDROME

A natural compound found in green tea improves patient cognitive skills.

From the team led by Marie-Claude Potier and Stéphane Haïk

Safety and efficacy of cognitive training plus epigallocatechin-3-gallate for cognitive improvement in young adults with Down's syndrome (TESDAD): a double-blind, randomised controlled, phase 2 trial. Rafael de la Torre et al. The Lancet Neurology, juillet 2016, 15(8): 801-810.

RARE DISEASES

A drug with proven efficacy against myoclonic dystonia.

From Emmanuel Flamand-Roze in the team led by Marie Vidhaillet and Stéphane Lehericy

A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia. Hainque E et al. Neurology. 2016 May 3;86(18):1729-35

PRIMARY PROGRESSIVE APHASIA

A pretherapeutic study shows beneficial effects of direct current transcranial stimulation.

From Marc Teichmann and Antoni Valero-Cabré in the team led by Richard Lévy and Bruno Dubois

Direct current stimulation over the anterior temporal areas boosts semantic processing in primary progressive aphasia. Teichmann M, Lesoil C, Godard J, Vernet M, Bertrand A, Levy R, Dubois B, Lemoine L, Truong DQ, Bikson M, Kas A, Valero-Cabré A. Ann Neurol. 2016 Sep 19.

ON THE START-UP SIDE

EPILEPSY

Smart connected clothing to diagnose epilepsy.

Bioserenity, managed by Pierre-Yves Frouin, developed the Neuronaute, a medical device already in use in 30 public hospitals (CE-certified)

FOR BRAIN TUMORS, ULTRASOUND TO INCREASE TREATMENT DIFFUSION

with the "SonoCloud®" ultrasound device developed by CarThera
By CarThera

Clinical trial of blood-brain barrier disruption by pulsed ultrasound.

Alexandre Carpentier and al. Science Translational Medicine, 15 Jun 2016

PARKINSON'S : Helping patient rehabilitation with a video game, TOAP RUN, with proven efficacy in reducing walking and balance disorders

By Marie-Laure Welter and Pierre Foulon, Brain e-novation

MULTIPLE SCLEROSIS

A mobile app for patient evaluation and monitoring at home to provide better care

By Ad Scientiam

ICM: REVOLUTIONARY, OPEN RESEARCH

RESEARCH TEAMS ARE INDEPENDENT, FULLY LINKED TO ONE ANOTHER THROUGH TRANSVERSAL RESEARCH PROGRAMS THAT ENCOURAGE POOLING OF SKILLS. FUNDAMENTAL, CLINICAL AND TRANSLATIONAL RESEARCH COEXIST TO HELP DISCOVER NEW TREATMENTS AS QUICKLY AS POSSIBLE AND MAKE THEM AVAILABLE FOR PATIENTS.

5 FOUNDATIONAL VALUES FOR OUR INSTITUTE, A BREAKTHROUGH ACCELERATOR

TRANSLATIONAL RESEARCH

A back-and-forth between fundamental and clinical research. It helps patients have faster access to innovations in diagnosis and therapy. This is the foundation of all research carried out at ICM.

MULTIDISCIPLINARY RESEARCH

Researchers, doctors, biologists, pharmacologists, mathematicians, engineers, physicians, IT specialists... ICM brings together multidisciplinary individuals that work closely together.

TRANSVERSAL RESEARCH

A breakthrough in one illness can lead to discoveries in others, which is why ICM encourages open research with transversal projects (neuroimmunology, for example).

INNOVATIVE RESEARCH

With incubated startups that develop treatments with researchers, ICM displays its uniqueness and desire to explore all types of innovation (patents, industry partnerships, living lab...).

ATTRACTIVE RESEARCH

The Institute is internationally attractive thanks to its scientific reputation and impact in translational research. Resources are available for researchers (platform quality platforms), as well as high-level scientific interactions, independence when it comes to combined direction, and encouraging risk-taking. ICM collaborated with internationally-renowned research centers and attracts talented young researchers from around the world: 30% are from another country.

AN AMBITIOUS RESEARCH PROGRAM: "BIG BRAIN THEORY"

Ambitious research projects at the frontier of various fields were implemented with the Big Brain Theory program. This call for internal transversal projects aims at encouraging innovative, original, and high-risk initiatives thanks to collaborations between the various teams and platforms within the Institute. 15 very promising initiatives were selected and financially supported to explore new research directions. In order to remain competitive and produce high-level research, ICM encourages risk-taking and breakthrough innovation.

FUNDAMENTAL RESEARCH

LncPD : Discovering new, unexplored DNA areas involved in Parkinson's disease.

MOCONET : Researching cortical networks in experimental models of Down syndrome.

CLINICAL RESEARCH

DIEP : Researching the impact of D2HG, a molecule produced by certain tumors, on the modulation of neighboring immune cell modulation.

DYNAMO : Modeling Alzheimer's disease progression to improve diagnosis and treatment.

MS-BIO-PROGRESS : Designing an innovative instrument to evaluate multiple sclerosis progression.

LUCID DREAM : Researching lucid dreams to understand gesture sequence learning and automation.

TECHNOLOGY AND METHODOLOGY

NG2DB2D - Next-Generation NeuroGenomics DataBases and Big Data : Creating a clinico-genetic database to understand complex pathologies.

CLINICAL AND FUNDAMENTAL RESEARCH

COG_BLIND : Decoding information in the visual cortex of patients with congenital blindness.

BIGPARK : Identifying new genes involved in Parkinson's disease to develop new treatment opportunities.

iTargetOPC : Targeting oligodendrocyte precursors, cells responsible for myelin sheath development in the central nervous system, as potential treatment for glioblastoma.

LIBERATE : Understanding the evolution of communication between various cortical areas in normal and pathological aging.

FUNDAMENTAL RESEARCH, TECHNOLOGICAL AND METHODOLOGICAL DEVELOPMENT

MAXIMS : Verifying the specificity of MRI biomarkers in detecting brain lesions.

ACTIMYEL : Role played by neural activity in (re)-myelination control.

FUNDAMENTAL RESEARCH, CLINICAL RESEARCH AND TECHNOLOGICAL AND METHODOLOGICAL DEVELOPMENT

ISIS : Understanding the underlying mechanisms of reduced oxygen supply to the brain.

MAJOR SCIENTIFIC AWARDS WON BY OUR RESEARCHERS

OUR RESEARCHERS CHANNEL THE SPIRIT OF CHARCOT, MAKING HIS VALUES THEIR OWN.



BENEDETTA BODINI
Neurologist at Pitié-Salpêtrière Hospital and Inserm researcher in the “Central nervous system myelination mechanisms” team at ICM

🏆 **MARIE-ANGE BOUVET-LABRUYÈRE AWARD** for the development of a new imaging technique for multiple sclerosis
> Publication with Bruno Stankoff, team leader at ICM, recognized as one of the 5 best publications of 2016 on multiple sclerosis by Lancet Neurology



EDOR KABASHI
Leader of team “Treatment of Amyotrophic lateral sclerosis: from genetics to zebrafish” at ICM

🏆 **PAULO GONTIJO INTERNATIONAL MEDICINE AWARD** for his research on development of new models and treatment options in Amyotrophic Lateral Sclerosis (ALS).



BASSEM HASSAN
Leader of team “Neural Development” at ICM

🏆 **PAUL G. ALLEN FOUNDATION “DISTINGUISHED INVESTIGATOR” AWARD** for his work on the frontier of neural network and behavioral development



PHILIPPE FOSSATI
Psychiatry Professor at Pitié Salpêtrière Hospital and Pierre et Marie Curie University, “Study of emotions and social interactions” team leader at ICM

🏆 **2016 HALPHEN PRIZE FROM THE PHILIPPE AND MARIA HALPHEN FOUNDATION**, for his work on depression



CLAIRE WYART
Leader of team “Probing dynamic sensory-motor integration in spinal circuits” at ICM

🏆 **FENS-KAVLI SCHOLARS 2016** by the Federation of European Neuroscience Societies and the Kavli Foundation
🏆 **EMBO YOUNG INVESTIGATOR PROGRAM**
🏆 **NEW-YORK STEM CELL FOUNDATION (NYSCEF) ROBERTSON AWARD**



LIONEL NACCACHE
University professor, hospital practitioner, Clinical Neurophysiology Department chief at Pitié-Salpêtrière University Medical Center in Paris and team leader at ICM

🏆 **LAMONICA AWARD** in Neurology for his work on consciousness



LUCE DAUPHINOT
CNRS Engineer in the team led by Stéphane Haïk and Marie-Claude Potier at ICM

🏆 **CNRS CRISTAL MEDAL** for her work on single cells



CHRISTIANE SCHREIWEIS
Researcher in Luc Mallet’s team, on “Behavior, emotion and basal ganglia”

🏆 **L’ORÉAL-UNESCO GRANT** as part of the l’Oréal-UNESCO “For Women and Science” program, for her research using innovative methods on repetitive behavior, as observed in OCD and Gilles de la Tourette Syndrome.

- FOCUS -

EUROPEAN RESEARCH COUNCIL GRANT: CLOSE TO 10 YEARS OF EXCELLENCE

ERC Grants are prestigious awards hailing from a high-level European research program that aims at supporting talented researchers with ambitious and innovative scientific projects. These grants were implemented in 2007 with the Lisbon Treaty and founding of the ERC, and have since supported over 7,000 projects and over 50,000 researchers for a total budget of nearly 12 billion euros. ERC grants are awarded in very diverse research fields, from mathematics to social science and humanities, life science or physics.

IN 2016, 3 ICM RESEARCHERS WERE AWARDED A GRANT TO SUPPORT THEIR RESEARCH.



STANLEY DURRLEMAN
ERC « STARTING GRANT »

Expert in mathematical modelling of neuroimaging data, INRIA researcher part of the ARAMIS team at ICM

Project: Modelling the brain to diagnose and treat neurodegenerative illness

Hopes to: Design numerical models of the brain showing the effect of neurodegenerative diseases on brain structure, function and metabolism; Use models to implement early diagnosis and reliable prognosis.



STÉPHANIE BAULAC
ERC « CONSOLIDATOR GRANT »

Expert in epilepsy genetics, co-manager of the “Epilepsy genetics” team at ICM

Project: Understanding the spectrum of severity in familial focal seizures

Hopes to: Verify an initial experimental model for the pathology; Decode the processes involved in epilepsy linked to the mTOR pathway; and Consider new treatment opportunities.



EDOR KABASHI
ERC « CONSOLIDATOR GRANT »

Expert in genetics of amyotrophic lateral sclerosis, leader of team “Treatment of Amyotrophic lateral sclerosis: from genetics to zebrafish”

Project: Research on Amyotrophic lateral sclerosis in Zebrafish to identify new treatment opportunities

Hopes to: Identify new molecules to fight ALS.

PASSING ON KNOWLEDGE

LEARNING AND TRAINING AT THE HEART OF THE INSTITUTE'S MISSION

DEVELOPING CUTTING-EDGE RESEARCH IS DEEPLY LINKED TO SHARING KNOWLEDGE AND FOSTERING NEW COLLABORATIONS. TO PASS ON AND SHARE KNOWLEDGE ON A NATIONAL AND INTERNATIONAL LEVEL, IN COLLABORATION WITH PIERRE AND MARIE CURIE UNIVERSITY, WE IMPLEMENTED AMBITIOUS SEMINAR PROGRAMS, SUMMER SCHOOLS, AS WELL AS STUDENT AND CLINICIAN EXCHANGES WITH PRESTIGIOUS INTERNATIONAL INSTITUTIONS. THANKS TO THE IHU PROGRAM AWARDED TO ICM, LEARNING AND TRAINING ACTIVITIES IN PLACE SINCE 2013 HAVE BECOME A PRIORITY.

PROMOTING SCIENCE

STUDENT FELLOWSHIPS PROGRAM

The "Student fellowship" program is a short-term exchange program for Master's or Doctoral students to help share the expertise of international institutions (Massachusetts Institute of Technology, Florey Institute of Neuroscience and Mental Health) and create opportunities for potential collaboration.

WORKSHOP CALL FOR PROJECTS

This call for projects is dedicated to ICM researchers and clinicians, to organize international seminars within the institute and promote their skills and expertise among their peers to foster collaboration. 2016 thematic were optogenetics, translational and multi-modal MRI and neurodegenerative illnesses in collaboration with Yale.

VISITING PROFESSOR CALL FOR PROJECTS

This call for projects aims at welcoming internationally-renowned senior researchers to ICM to pass along their knowledge. In 2016, we were pleased to welcome Professor David Hafler, President of the Department of Neurology at New Haven Medical School.

PROMOTING CLINICAL RESEARCH

THE MOVE

The Move is a unique program designed for medical students by Professor Emmanuel Roze, researcher and clinician. The Move is an innovative learning program by simulation that uses miming to teach medical students neurological semiology, meaning the clinical expression of neurological illnesses. The program, developed on a national and international level, is a remarkable example of innovation in education.

CLINICIAN EXCHANGE PROGRAM

A clinician exchange program with Yale, within the Neurology department at Pitié Salpêtrière Hospital, allows clinicians to learn how our departments work and how we work.

PROGRAM FOR PARAMEDICAL STAFF

A program designed for paramedical staff in partnership with the Public Health and Nursing School to develop innovative paramedical research projects.

A CROSS-DISCIPLINARY APPROACH

SUMMER SCHOOL : BRAIN TO MARKET

"The Brain to Market" summer school is a yearly program that combines translational neuroscience and entrepreneurial training through intensive training to foster new projects, new initiatives and new ways of approaching neurological illnesses. The 2016 thematic was epilepsy, with 50 national and international participants.

POST-DOCTORAL PROGRAM


Attracting post-doctoral researchers with a degree in other fields than neuroscience such as mathematics, IT, healthcare economics... to apply their knowledge to a specific topic.

WHAT'S NEXT?

MAINTAINING AND DEVELOPING CURRENT PROGRAMS.

CREATING AN INTERNATIONAL MASTER'S DEGREE FOCUSED ON NEURODEGENERATIVE ILLNESSES IN RELATIONSHIP WITH PIERRE ET MARIE CURIE – SORBONNE UNIVERSITY.

IMPLEMENTING AN INTRODUCTION TO RESEARCH INTERNSHIP FOR MEDICAL STUDENTS, THE STARE PROGRAM, BASED ON AN INITIATIVE DEVELOPED BY PROFESSOR JEAN-YVES DELATTRE TO HELP 3RD YEAR MEDICAL STUDENTS DISCOVER RESEARCH AND FOSTER NEW CALLINGS TO DEVELOP TRANSLATIONAL RESEARCH.



"EDUCATION IS AN ESSENTIAL PATHWAY FOR ICM, TO GENERATE AMBITIONS, DEVELOP NEW COLLABORATIONS, OPEN OURSELVES UP TO CROSS-DISCIPLINARY APPROACHES ON RESEARCH PROJECTS WITH A LONG-TERM AND INTERNATIONAL STRATEGY."

ALEXANDRA AUFFRET,
DIRECTOR OF THE SCIENTIFIC AND MEDICAL AFFAIRS DEPARTMENT

AT THE CROSSROADS OF INTERNATIONAL AND NATIONAL RESEARCH

ICM IS PART OF AN INTERNATIONAL NETWORK THAT INCLUDES MAJOR NEUROSCIENCE CENTERS INVOLVED IN SHARED RESEARCH PROJECTS. THE INSTITUTE IS EMERGING AS AN ATTRACTIVE MEDICAL SCIENCE RESEARCH HUB FOR HIGH-LEVEL RESEARCHERS FROM AROUND THE WORLD.

With nearly 300 partnerships developed worldwide, ICM's international reach is on the rise. These collaborations are an opportunity to share our breakthroughs and carry out shared research programs. Exchange programs are also in place to develop training and skill-pooling. ICM aims to develop partnerships with institutions specialized in complementary fields to meet transversal needs.

INTERNATIONAL COLLABORATIONS



THE INSTITUTE OF NEUROLOGY (University College of London, Royaume-Uni) and the **DZNE** (Network of research centers focused on Neurodegenerative illness, Germany) with research partnerships. ICM hopes to co-develop training and education with these institutions.

YALE NEW HAVEN UNIVERSITY for a clinician exchange program.

UNIVERSITY OF CALIFORNIA - SAN FRANCISCO with the implementation of a Inserm-certified Associated International Laboratory with the team led by Bertrand Fontaine and Stephen Hauser.

THE MNI (MONTRÉAL NEUROLOGICAL INSTITUTE) in Canada, with which ICM has organized joint events in the past and welcomed many researchers on a variety of topics.


THE FLOREY INSTITUTE (AUSTRALIA), for a student exchange program with short-term internships. Shared seminars with our researchers aim at fostering relationships in research and education.



ICM is part of an international network that includes major neuroscience centers involved in shared research projects. Research carried out at ICM is assessed by an International Scientific Committee composed of experts from around the world. ICM is therefore both an attractive medical and scientific research hub for high-level researchers as well as a generator of novel scientific information on an international level. Our research ambitions require close cooperation with the most prestigious French and international research institutions.

ICM is a cornerstones of the **GREATER PARIS RESEARCH NEUROHUB** (Neuropôle de Recherche Francilien - NERF) and the **PARIS SCHOOL OF NEUROSCIENCE** (École des Neurosciences de Paris - ENP), and partners with other high-level research centers throughout Paris: **PIERRE ET MARIE CURIE UNIVERSITY, ÉCOLE NORMALE SUPÉRIEURE, VISION INSTITUTE, MIRCEN, NEUROSPIN, PASTEUR INSTITUTE...**

RESEARCH AT ICM IS DEVELOPED IN COOPERATION WITH MAJOR FRENCH NEUROSCIENCE CENTERS, AMONG WHICH:



THE CLINICAL INVESTIGATION CENTER, CIC TOWARDS TAILORED AND PERSONALIZED PATIENT TREATMENT

THE CLINICAL INVESTIGATION CENTER OR CIC (INSERM, AP-HP), HOUSED IN THE ICM, IS AN EXCEPTIONAL PATHWAY BETWEEN RESEARCH AND CARE, OFFERING INNOVATIVE TREATMENT FOR PATIENTS AFFECTED BY NEUROLOGICAL ILLNESSES.



3 QUESTIONS FOR PROFESSOR JEAN-CHRISTOPHE CORVOL, CIC DIRECTOR

HOW DOES THE CIC WORK? WHAT ARE ITS MISSIONS? WHAT IS THE RELATIONSHIP WITH THE NERVOUS SYSTEM DISEASES HUB AT PITIÉ-SALPÊTRIÈRE HOSPITAL?

The CIC is located in ICM building, at the core of research. It maintains a strong relationship with the doctors working in the Nervous System Diseases hub at Pitié-Salpêtrière hospital. This means we can easily take laboratory discoveries right to the patient's bedside and vice versa. The Center aims at improving our understanding of the human brain and pathologies, as well as granting patients rapid access to breakthroughs in research to improve patient diagnosis and care.

In 2016, the CIC officially merged with the Center for Therapeutic Assessment (Centre d'Évaluation Thérapeutiques - CET), a similar institution located in the Department of Neurology at Pitié-Salpêtrière Hospital. The goal is to create a full clinical research platform, from ICM research on early drug development to assessment and improvement of care, access to major international trials and innovative medical devices with the Living Lab. 172 drug trials are in progress throughout the Nervous System Diseases hub, half of which are at the CIC-CET, in various fields of neurology and psychiatry.

WHAT ARE SOME HIGHLIGHTS OF 2016 CLINICAL TRIALS THE CIC TOOK PART IN, AND THE MAJOR TRIALS TO COME?

The CIC took part in three major multiple sclerosis clinical trials that demonstrated the efficacy of two new treatments for progressive forms

of the disease. Trials at the CIC also demonstrated the existence of markers for remyelination potential and neuronal loss in patients, allowing prediction of disease progression and selection of the best possible treatment for each patient.

In Parkinson's disease, the CIC is taking part in a European trial on deferiprone, an iron chelator with a supposed effect in decreasing iron deposits in neurons and with a neuroprotective effect. The NS-PARK/FCRIN network, that brings together the 24 centers specialized in Parkinson's disease in France, is also involved in the trial (H2020 European financial support, Lille University Medical Center as promoter). We are also coordinating a trial on dyskinesia treatment, also called involuntary movements, thanks to the same clinical research network and in partnership with CleveXel.

Another great success for 2016 is the study carried out by Emmanuelle Roze, proving the efficacy of zonisamide in treating myoclonic dystonia, a rare illness.

Finally, a study is underway in collaboration with Professor Richard Lévy's team to give a detailed assessment of apathy, lowered activity levels linked to decreased motivation in many neurodegenerative illnesses. This is done using the PRISME "real-life" platform, used for observation and analysis of patient behavior in semi-natural conditions.

Starting in 2017, we will be launching various trials including a collaboration

3 PILLARS : ETHICS, SAFETY, QUALITY

The CIC takes ethics and safety very seriously when it comes to studies. Participants in trials are made aware of the benefits and possible risks. Each study receives a favorable opinion from an ethics committee as well as the drug administration (ANSM) before launching. Additionally, the drugs involved in clinical trials all go through a safety assessment process before the trial starts.


CIC QUICK FACTS

172 CLINICAL TRIALS IN PROGRESS



DAILY CONTACT WITH 650 RESEARCHERS AND CLINICIANS

7 000 PARTICIPATING PATIENTS OF THE CLINICAL TRIALS

STEPS IN CLINICAL RESEARCH



Innovation <---> Transfer <---> Application





CONVERSATION WITH PROFESSOR JEAN-YVES DELATTRE, ICM MEDICAL DIRECTOR AND NSD HUB CHIEF AT THE PITIÉ-SALPÊTRIÈRE HOSPITAL

THE NERVOUS SYSTEM DISEASES HUB, NSD

TO GIVE PATIENTS ACCESS TO THE LATEST BREAKTHROUGHS IN TREATMENT

WITH OVER 80,000 CONSULTS PER YEAR, THE NERVOUS SYSTEM DISEASES HUB, (OR NSD HUB) IS ICM'S HOSPITAL COUNTERPART. IT POOLS TOGETHER THE DEPARTMENTS OF NEUROLOGY, PSYCHIATRY, FOLLOW-UP CARE AND REHABILITATION, AS WELL AS THE NEUROPHYSIOLOGY AND NEUROPATHOLOGY DEPARTMENTS AT PITIÉ-SALPÊTRIÈRE HOSPITAL. THE NSD HUB'S ACTIVITY IS BASED ON THREE PILLARS: DIAGNOSING, TREATING, AND REHABILITATING.

THE NSD HUB IS A PARTNER OF CHOICE FOR ICM, HOW DOES THEIR COLLABORATION WORK?

The collaboration between ICM and the NSD Hub is growing, and doing well. The "Clinical Research" entities of ICM and NSD Hub are on their way to becoming a single entity, a neuroscience clinical research powerhouse at Pitié-Salpêtrière Hospital. We are also putting the finishing touch on a clinical research facility managed by Professor Jean-Christophe Corvol. The driving forces behind it come from the hub (AP-HP), INSERM, and ICM (doctors, paramedical staff, statisticians, etc.). It should be fully operational by the end of 2017.

WHAT STEPS DOES A PATIENT WITH A NERVOUS SYSTEM ILLNESS GO THROUGH AT THE NSD HUB?

The first step is establishing the correct diagnosis using our medical experts and the technical platform we have on-site. Next, we draw up a healthcare plan suited to the patient with the help of a multidisciplinary team. At each and every step, we have to ask ourselves the

following questions: did we use the most modern techniques available, here at ICM, for the patient? Is there a research project planned to improve current knowledge on the patient's illness or treatment that we can ask the patient to participate in?

WHAT ARE SOME BREAKTHROUGHS FOR 2016?

As I said earlier, one of the major advances for 2016 was the launch of a clinical research unification process between the hub and ICM with Professor Jean-Christophe Corvol. The resulting asset goes much further than the CIC-CET. 172 clinical trials are currently in progress led by NSD Hub and ICM teams - quite a lot. Another progress we've made is going forward in planning the "Neurotrials" and "Neurocatalyst" projects, which will help us have the full clinical research process on-site, from proof of concept of a drug to large-scale assessment in Phase III studies on a national or international level. We've also implemented specific training to develop a research culture among the hub's paramedical staff (nurses, assistant nurses, physical therapists,

psychologists...): we want every single member of our staff to be part of their own research, be it in healthcare or quality of life, and ICM is helping them with training on methodology. The Living Lab is a great example of collaborative research. Clinicians, researchers, paramedical staff, patients and developers work hand in hand to design, develop and create innovative instruments for improved patient care. Projects for a new "medical beds", 3D cranioplasty as well as a cane emitting light to help Parkinson's patients start up are all examples of real-life applications that help our patients and improve their daily life.

WHAT ARE SOME MAJOR UPCOMING PROJECTS?

For the first time, the NSD hub is going to dedicate part of its budget to supporting a clinical research project initiated by a young doctor. It is absolutely essential to give young colleagues the drive to invest in clinical research as early as possible in their career. Another project we have right now is developing indicators to help us monitor

2016 HIGHLIGHTS

PROVEN EFFICACY OF A DRUG

TO TREAT MYOCLONIC DYSTONIA, A RARE ILLNESS, WITH RESEARCH CARRIED OUT BY EMMANUELLE ROZE.



precisely everything that is going on in clinical research in our 10 departments - how many innovative trials we have offered our patients, how many patients we are involving per month, etc. - with the hope that as many patients as possible can benefit from new treatments. Designing an innovation-centered department means getting used to that culture, which is why we have started gathering these indicators.

We also hope to implement ICM "Clinical research team" certification for NSD hub departments with a deep involvement in this field. Rigorous assessment by an international jury would be a prerequisite, quite like what is already in place for fundamental (laboratory) research teams at ICM, to improve our clinical research expertise.

Finally, some great news is that we are opening a new building, "Paul Castaigne", in December 2019. The building will be dedicated to Neurology for the entire Pitié-Salpêtrière Hospital. This huge project is a great opportunity for us to rethink our organization and create a tighter link

between medical care and clinical research, both dedicated to our patients. Along with this vast work in progress, Professor Bruno Dubois is driving a project to consider building a facility right next door dedicated to clinical research on neurodegenerative diseases, with close ties to ICM. This would be an opportunity to build a fast-track between the NSD hub and ICM to develop innovative treatment.

IN YOUR EYES, WHAT DOES TOMORROW'S MEDICAL WORLD LOOK LIKE?

It will be predictive, and fully tailored to patients who are informed and looking to make their own decisions. Medicine has always progressed by identifying different entities that can be impacted by different treatments, in what looks at first like a common framework. I don't see why this should change at all. I also strongly believe that we will listen to what patients have to say, including when it comes to deciding what their future holds in the case of terminal and disabling illness.

THE INSIGHT PROJECT

COORDINATED BY BRUNO DUBOIS, PROVIDING AN EXCEPTIONAL AMOUNT OF RESEARCH ON VERY EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE.

DESCRIPTION OF NEW SYMPTOMS

IN PATIENTS WITH BEHAVIORAL DISORDERS AND AFFECTED BY APATHY, THANKS TO WORK DONE BY THE BEHAVIORAL NEUROPSYCHIATRY UNIT (UNITÉ DE NEUROPSYCHIATRIE COMPORTEMENTALE - UNPC) WHERE NEUROLOGISTS, PSYCHIATRISTS AND RESEARCHERS COLLABORATE.



HOW DOES THE RESEARCH & TECHNOLOGY DEVELOPMENT OFFICE (DAR) TRANSFORM DISCOVERIES MADE BY OUR RESEARCHERS INTO THERAPIES?

5 QUESTIONS TO ALEXIS GÉNIN, DIRECTOR OF THE RESEARCH & TECHNOLOGY DEVELOPMENT OFFICE



“OUR GOAL IS TO DETECT PROMISING SCIENTIFIC BREAKTHROUGHS TO DEVELOP THEM INTO THERAPEUTIC SOLUTIONS AS QUICKLY AS POSSIBLE”

ALEXIS GÉNIN, DIRECTOR OF THE RESEARCH & TECHNOLOGY DEVELOPMENT OFFICE.

This mission starts with early detection of research results that could lead to applications, their protection with patents, financial support for proof of concept to get from an idea to a proven idea, and finally, finalizing inventions and new drug or medical technology development. All of this is possible thanks to our “Carnot Institute” certification that supports development of research partnerships and transfer of technology between public research and businesses, as well as the Living Lab and iPEPS-ICM, a business incubator and France’s top innovation accelerator dedicated to brain illnesses. 16 innovative startups working in digital technology, medical technology and drug development are currently incubated.

HOW DOES THE DAR DEVELOP DISCOVERIES INTO THERAPIES?

The first phase is based on interaction, detailed discussions with researchers and doctors to find comparable data that may exist elsewhere in order to characterize how new and innovative the finding is. This phase is always undertaken secretly, and this is when we decide to grant an initial package for financial support. As a Carnot Institute, we have access to resources to help us verify an idea’s value or results, and their potential development into products to help patients.

The second phase is protection of intellectual property, when a patent is filed. After this phase, the project can “mature”, with the help of industry partners and investors. At times, we invest in projects ourselves to help push them as far as we can until a partner can take over and sponsor product development.

DID THIS PROCESS CHANGE AT ALL IN 2016?

We have been taking a much more proactive approach in order to lead product development ourselves by founding startups. ICM isn’t only bringing expertise and skill to the table to help other startups develop drug, it is now a product developer itself. I would say that was the major change of the year.

ICM RECENTLY RECEIVED “CARNOT 3” CERTIFICATION, WHAT CHANGES ARE INVOLVED?

The main Carnot missions remain the same: professionalism in our relationship with industry players, responsiveness, integration within a multi-thematic network of institutes from energy to nanotechnology and health. Along with our colleagues in the Carnot galaxy, we create pathways between the various industrial

fields to foster successful developments, with our eyes turned towards the rest of the world to position the Carnot brand on an international level.

In 2016, Carnot financial support helped bring a dozen projects to fruition, and supported the filing of 7 patents, the Institute’s ongoing commitment to quality, and international development. In February, ICM was part of a major Carnot event: the French American Innovation Days, in Boston, where the Carnot Institute model in healthcare was presented to the American business ecosystem.

WHAT ARE SOME OF THE DAR’S MAJOR ACHIEVEMENTS FOR 2016?

First of all, I’d like to mention our work in coordinating FindMed, a network of 10 major Carnot institutes. This shows that ICM can position itself as a point of reference in business services on a

RESEARCH & TECHNOLOGY DEVELOPMENT OFFICE: WHAT TO KNOW

One of the highest growths among the **Carnot Institute** network

27 companies incubated at iPEPS-ICM since 2012, **3 are international**

200 industry partnerships

OVER 50 PATENTS

2 laboratories, recipients of the « **INNOVATION 2030** » : **Bio-electrics lab and Brain eNovation**



Over **100 million** euros raised by our startups – **120** entrepreneurs on-site

CERTIFICATION of 2 Biological Resource Center platforms

OPENING OF THE LIVING-LAB where patients, researchers, clinicians and developers work together to design new therapeutic solutions

1 DRUG developed by MEDDAY to fight multiple sclerosis

1 TELEMEDICAL platform created by shared laboratory **Brain eNovation**

Diagnostic solutions for epilepsy developed by **BIO SERENITY** installed in over **30 HOSPITALS**



MOBILE APPS to monitor multiple sclerosis developed by **Ad Scientiam**

In a world first, **Carthera**, medical device designer and developer, was granted **5,7 million** euros in financial support by the French administration.

national level. In fact, partnerships with our technological platforms grew over 25% in 2016.

Next is the Living Lab, certified to join the European Living Lab network called ENOLL. The first functioning prototypes to come out of the Lab have already been developed on an industry level, a sole 18 months after the Lab was started. Finally, receiving “French Tech Ticket incubator” certification by the Ministry of Economy illustrated our ability to support international companies. It’s important to note that in 2016, startups incubated with us raised over 60 million euros in funding.

HOW DOES THE DAR MEET CURRENT CHALLENGES IN THE DEVELOPMENT OF NEW THERAPEUTIC OPTIONS?

We are hard at work developing new ways to use existing medication, and

are working with excellent chemists specialized in natural molecules to help identify future drugs using traditional medicine.

We also need to employ other approaches: businesses specialized in medical technology development, for example, are very dynamic and can give us a different outlook on how to think about illness. Wearable medical devices, mobile applications, smart objects, and therapeutic gaming could become part of global patient care. Active prevention is also an interesting field to look at, especially nutrition and physical activity, if we can prove their efficacy and integrate them into structured patient programs. We really are trying to understand patient care as a whole rather than take a solely medication-based approach, and are attempting to develop integrated solutions where drugs are one element among many

others used to halt disease progression. Our mid- and long-term mission is to bring therapeutic solutions for patients to market. Starting 2017, we hope to prove clinical efficacy for one project and verify the benefits of 2 to 3 medical technologies for patient use. Thanks to the Future Investments Program (IHU), we will have support from a new project, NeuroCatalyst, that will allow greater investment in clinical research. Additionally, in 2017 our expansion to the Station F startup campus will allow new “digital” healthcare startups to come to life and will help foster innovation interactions.



THE LIVING LAB

DESIGNING FUTURE MEDICAL INNOVATIONS TOGETHER, TODAY

5 QUESTIONS FOR ALEXIS STEINER, LIVING LAB MANAGER

WHAT IS THE LIVING LAB, EXACTLY?

It is a collaborative platform where patients and hospital staff are right at the heart of innovation design. It is a free space, away from hospital life, where different approaches and opinions from researchers, engineers, doctors, hospital staff, patients, students, startups, and more can interact to come up with the most innovative ideas possible.

ITS MISSION

It aims to create innovative medical devices to improve patient care in neurology and psychiatry. Our goal is to launch our innovations and bring them to market quickly thanks to help from the Research and Technology Development Office, either with operating licenses negotiated with industry players, collaborations with businesses, or even by creating dedicated startups.

HOW DOES IT WORK?

To put forward a solution, we need to identify a need, first of all, and describe it with the help of patients and hospital staff. Next, we try to find a creative solution to this need by imagining what the ideal solution would look like. Finally, we bring the idea to life as quickly as we can by testing a prototype from a technological, clinical, and financial point of view.

SOME NEW PROJECTS IN 2016

Encouraging functional rehabilitation after patients are discharged from the hospital, diagnosing a risk of reduced autonomy to improve elderly patient support, treating

feeding disorders (children experiencing trouble dealing with food) with therapeutic cards, improving cranioplasty in the operating room, robotics to support cognitive rehabilitation of stroke or head injury patients, allowing prediction of behavioral crises in patients with autism: these are some of the projects developed at the uCIL Living Lab.

2 SUCCESS STORIES FOR 2016

With the support of a patient from the France Parkinson Association, we developed a cane that emits visible light to get rid of the freezing effect, when patients are suddenly unable to move, and to help Parkinson's patients take a first step. Thanks to support from an industry partner and France Parkinson, we hope to make this device available to every patient soon.

A topic that we spent some time on is improving everyday life for patients with long-term hospital stays and how to give them some privacy. We collaborated with a design school, hospital staff and patients and came up with a visually-pleasing mobile wall with an integrated night stand and technical supply unit (light, oxygen...) that isolates patients. A prototype was produced with external suppliers and approved by all the participants in the project. A hospital furniture supplier is on board to produce and sell the product.

UPCOMING PROJECTS FOR 2017

To increase patient implication in cognitive rehabilitation, we created a robot in collaboration with AI MERGENCE, a startup. **THE ROBOT HELPS THE OCCUPATIONAL THERAPIST DURING THERAPY SESSIONS** at the hospital, and the patient can then bring it home where it provides assistance for rehabilitation exercises.

The project is financed by a Carnot call for projects, and AI MERGENCE will enter the incubator in 2017.

A test provided free of charge to detect **CEREBELLAR DISORDERS (CCFS)**. Blueprints to make the box will be available online for free, allowing anyone to make their own and take the test at home.

OPENING OF A FABLAB ET ICM, a prototyping workshop right at the heart of the building in collaboration with the CENIR platform and BEBG team.

2016 HIGHLIGHTS

10 CREATIVITY WORKSHOPS

100 individuals from diverse backgrounds, doctors, patients, paramedical staff, designers, sociologists, developers, engineers

300 IDEAS

10 PROJECTS

in close collaboration with hospital staff and patients, including 4 finalized in 2017

ENOLL CERTIFICATION (European Network of Living Labs)

The world's only neurology living lab

INTERNATIONAL REPUTATION

FINDMED CREATING PATHWAYS BETWEEN ACADEMIA AND THE DRUG INDUSTRY

FINDMED is a consortium coordinated by ICM, with Damien Salauze as Operations Director. It is composed of 10 Carnot Institutes and aims at implementing partnerships with small to mid-size French drug manufacturers.

FINDMED is a French governmental initiative to support competitiveness of drug manufacturers by granting them access to academic research and the associated technological means.

The technological platforms of the various Carnot Institutes in the consortium blend cutting-edge equipment with expertise, allowing industrial partners to bring their projects to life and innovate with equipment tailored to their needs.

ICM's nomination as project coordinator anchors the Institute as a leader in business services.



FINDMED KEY FIGURES

- 10 CARNOT INSTITUTES, INCLUDING 6 LEADERS IN THE HUMAN AND ANIMAL HEALTH FIELDS
- 175 CONTRACTS WITH INDUSTRY PLAYERS (EXCEPT LARGE GROUPS), INCLUDING
- 32 VERY SMALL BUSINESSES (1.2 M€ REVENUE)
- 66 SMALL AND MID-SIZED BUSINESSES (5.2 M€ REVENUE)
- 30 INTERMEDIATE BUSINESSES (2.8 M€ REVENUE)
- 56 CUTTING-EDGE TECHNOLOGICAL PLATFORMS

AN INCUBATOR TO SUPPORT STARTUPS



ICM'S IPEPS INCUBATOR FOLLOW YOUNG INNOVATIVE COMPANIES THROUGHOUT THEIR DEVELOPMENT TO TRANSFORM IDEAS INTO THERAPIES. THEY BENEFIT FROM AN IDEAL ENVIRONMENT, AT THE HEART OF A CUTTING-EDGE RESEARCH INSTITUTE, ITSELF RIGHT IN THE MIDDLE OF A HOSPITAL"

JULIEN ELRIC, START-UP MANAGER AT THE RESEARCH & TECHNOLOGY DEVELOPMENT OFFICE.

FINDING THE PERFECT PROJECT

The incubator's goal is to develop discoveries, ideas and innovations from ICM laboratories or from the outside. A project's potential is evaluated in collaboration with ICM researchers and clinicians that take part in the decision to create an ICM-incubated company. The incubator also has a forward-looking approach, taking part in international conventions, scientific conferences and competitiveness centers to identify projects that could be a good fit with ICM.

RAISING FUNDS

The incubator helps companies raise funds as drug and medical device develop is very costly. ICM startups have succeeded in raising over 100 million euros since 2012 both in private and public funds. To support companies in their development, the incubator relies on various partners including the Public Bank for Investment (Banque publique d'investissement), the primary financial partner for startups, and a vast network of investors.

ACCELERATING INNOVATION

Supporting startups is an everyday affair, to help them transform their idea into a profitable business that will succeed in bringing an innovation to market. Some activities are: reviewing business plans, helping create a pitch, developing a company presentation for potential investors, introducing them to investors, streamlining costs, and more.



FROM BIOTECHNOLOGY TO E-HEALTH

The 16 startups incubated at ICM cover all facets of neuroscience, from medical technology, to biotechnology and e-health.

ENCOURAGING INTERACTION

Cross-fertilization is one of the incubator's core ideas: encouraging interaction and collaboration between companies through staff and equipment pooling, through conversations between researchers and clinicians... This collaborative environment is what leads our projects to success.

A TURNING POINT

In 2016, a truly proactive approach was implemented with partnership development, a search for foreign companies to build an international vision, and even stronger support through share ownership for some companies.

LES START-UP DE L'ICM



ACTIVITY: Innovative medical devices designed to treat brain illnesses.

2016 HIGHLIGHT: financial support of 5.7 million euros in the "Research and Development Projects for Competitiveness" ("Projets de R&D Structurants Pour la Compétitivité" - PSPC) project of the Future Investments Program (Programme d'Investissements d'Avenir - PIA), led by the General Commissioner for Investment (Commissariat Général à l'Investissement - CGI) and operated by Bpifrance for its DOME project.



ACTIVITY: Non-invasive methods based on spinal cord stimulation (trans-spinal direct current) for treatment of patients with motor disorders.



ACTIVITY: medical devices for neurology/neurosurgery, specifically for patients with intracranial hypertension

2016 HIGHLIGHT: Official launch of the company. In vivo proof of concept, Scientipôle interest-free 'honor' loan and PIA (BPI) financing



ACTIVITY: Neuroprotective molecules used against neurodegenerative illnesses such as Parkinson's disease.

2016 HIGHLIGHT: Founded in February 2016 and incubated at ICM in September. Obtained an exclusive license to use an ICM molecule that may have a major effect in treating Parkinson's. 2016 Scientipôle Initiative Winner and recipient of the Emergence French Tech Grant.



ACTIVITY: Innovative digital instruments in healthcare, especially therapy video games.

2016 HIGHLIGHT: Publication of results in Journal Of Alzheimer's Disease verifying efficacy and patient tolerance in a pilot usability and acceptability study of therapeutic video game X-TORP designed for patients with Alzheimer's disease and associated illnesses.

Financing of a new Europe-wide study in partnership with Rabdoud University in the Netherlands for therapeutic video game TOAP Run designed for patients with Parkinson's disease, within the H2020 program. Launch of the ReMinAry project to implement rehabilitation through Motor Imagery, based on the cognitive process whereby a patient mental simulated an action without actually performing it. The online platform www.curapy.com, that gathers therapeutic video games with proven efficacy in clinical trials, is finishing up its "test phase" year with over 3,000 healthcare professionals signed up.



ACTIVITY: The Neuronaute, smart clothing for at-home epilepsy monitoring

2016 HIGHLIGHT: 4 m€ revenue in 2016. Over 32 hospitals currently use their digital solutions.



ACTIVITY: Applications for improved patient care at home or in a hospital setting.

2016 HIGHLIGHT: 1 million euros raised and renewed partnership with Roche. Presentation of clinical trial results and proof of concept for their future medical device to the ECTRIMS. Several research contracts with the pharmaceutical industry.



ACTIVITÉ : Screening instruments for neuroprotective molecules in various neurodegenerative illnesses



ACTIVITÉ : Diagnostic de la maladie d'Alzheimer.



ACTIVITÉ : Measuring instruments to detect blood-brain barrier crossing (that prevents molecules from entering the brain) by molecules



ACTIVITÉ : Outils d'analyse biostatistique.



SOPHISTICATED TECHNOLOGICAL PLATFORMS FOR HIGH-LEVEL RESEARCH

HIGH-PERFORMANCE TECHNOLOGICAL PLATFORMS ARE NECESSARY TO ACHIEVE MEANINGFUL SCIENTIFIC BREAKTHROUGHS. ICM IS BOTH REVOLUTIONARY IN ITS DESIGN AND INNOVATIVE IN ITS ORGANIZATION, AS WELL AS UNIQUE IN ITS CUTTING-EDGE TECHNOLOGICAL EQUIPMENT. ICM RESEARCHERS WORK AT VARIOUS SCALES: FROM MOLECULES (DNA, PROTEINS,...) TO CELLS, TO INDIVIDUALS AS A WHOLE. AT EACH SCALE, INNOVATIVE TECHNOLOGY IS MADE AVAILABLE TO RESEARCHERS AND CLINICIANS. ICM PLATFORM NETWORK ENABLES TRANSLATIONAL RESEARCH, WITH AN IMPORTANT RELATIONSHIP FORGED BETWEEN RESEARCHERS AND CLINICIANS.

5 QUESTIONS FOR ETIENNE HIRSCH, DIRECTOR OF PLATFORMS

HOW DO WE ENSURE COMPETITIVE RESEARCH RESULTS?

Progress in biology and medicine needs strong technology and advice from the best experts in their field. In fact, most major discoveries are thanks to technical and methodological progress.

WHAT IS THE MISSION OF THE PLATFORMS?

The human brain is our body's most complex organ. Understanding how it functions and the associated pathologies means acquiring data at every level (molecular, cellular, neural network...) and at each moment. For ICM founders, it was important to give research teams the instrumental and organizational capabilities to meet their goals. From the start, ICM was structured around high-level technological and human resource pooling to necessary to research development. Beyond making innovative instruments and equipment available - high-performance microscopes, MRI, PET-MRI, high-speed sequencer... - the mission of our platforms is sharing technical skills and offering services and expertise. The platforms are open to the entire scientific community: ICM research teams, outside academic teams, incubated companies and outside companies.

These platforms are an opportunity for researchers to widen the scope of their research and exploration by giving them access to unique resources.

WHAT'S NEW FOR 2016?

In 2016, we launched a call for tenders to encourage platform competitiveness and incite them to develop methodological and technological research.

3 projects were financed with this call for tenders:

- The DISCO method to make brain tissue transparent and thus "peruse" through the brain and see neurons in 3D
 - Automation of gene analysis to implement experimental modelling
 - New functional testing to study activity of human neuron cultures, derived from induced pluripotent stem cells
- This R&D activity is essential to diversify the technological offer of our platforms and meet the needs of research teams. It is also an opportunity to provide a return on ICM's investment in our platforms and ensure its long-term viability.

OUR 2016 SUCCESS STORY?

Thanks to CENIR cutting-edge brain imaging, researchers in the team led by Stéphane Lehericy and Marie Vidailhet identified a marker in a pre-symptomatic variant of Parkinson's disease, in which patients present isolated behavioral disorders during REM sleep. This marker could be used as a diagnostic test for future patients. Thanks to the various cellular exploration techniques at CELIS, Olga Corti in Alexis Brice's team highlighted the cellular mechanisms

involved in certain familial forms or Parkinson's disease caused by a Parkin protein genetic mutation. They showed that the protein seems to act as a regulator of calcium channels between the endoplasmic reticulum and mitochondria, the cell's energy generator thought to play a pivotal role in the disease's various forms. Shedding light on this process that is responsible for the death of neurons involved in Parkinson's disease gives us new insight into possible therapeutic opportunities.

WHAT'S NEXT?

We hope to maintain and reinforce platform competitiveness with a second call for tenders, "research and development in 2017". We will also be assessing activities carried out by platforms that received investments from our public partners.

ICM PLATFORMS

ICM PLATFORMS FOLLOW A SILO ORGANIZATION BASED ON THEIR SCALE: MOLECULAR EXPLORATION, CELLULAR EXPLORATION, IMAGING, PRECLINICAL FUNCTIONAL EXPLORATION, FUNCTION EXPLORATION, BIO-INFORMATICS AND BANKS.

EXPLORATION MOLÉCULAIRE

- Genome analysis and development of viral vectors
- **iGenSeq** - genotyping-sequencing platform
- Genome analysis, detection of possible genetic mutations and identification of possible relationships between mutation and pathological signs.
- **iVector** - vectorology platform
- Production of viral vectors used for gene therapy used by ICM researchers in the hopes of "repairing" damaged DNA in patients.

CELLULAR AND MOLECULAR IMAGING

- 360° cellular observations, classic and photon microscopy
- 2-photon optogenetic electron microscopy, fluorescence microscopy, 3D microscopy, light sheet microscopy, etc.

PRECLINICAL FUNCTIONAL EXPLORATION

- Study of living organisms in experimental models
- **PHENO-ICMice** - Rodent Model Platform
- **PHENO-ZFish** - Zebrafish Model Platform

FUNCTIONAL EXPLORATION

- Study of living organisms using non-invasive and respectful methods, particularly adapted to both healthy volunteers and affected patients.
- **CENIR - Human MRI** - Research neuroimaging platform High-quality imaging instruments for brain and spine research.
- **CENIR- MEG/EEG** - Magnetoencephalography and Electroencephalography platform - Non-invasive methods for visualization of cerebral activity with millisecond precision.
- **CENIR- STIM** - Stereotaxic platform
- Program development and analysis using stereotaxic imaging data (uses include deep brain stimulation, drug-resistant epilepsy and radiosurgery)..
- **CENIR-PANAM** - Physiology and movement analysis platform
- Clinical and therapeutic research using non-invasive brain stimulation, motor control studies and multidisciplinary association of various techniques.
- **CENIR -Small Animal MRI** MRI Platform for small animals
- Experimental pathological model platform for assessment of new biomarkers, the study of pathology mechanisms, and drug assessment.

CELLULAR EXPLORATION

- Implementation of easy-to-handle cell cultures to reproduce and study nervous system pathology mechanisms.
- **CELIS** - Cell culture platform
- Cell models and cutting-edge technology used to study brain and spinal cord pathology, as well as screening of potential medication.
- **CELIS-E-PHYS** - Electrophysiology platform
- Record electrical activity within cells in various experimental conditions (isolated cells, tissue samples).
- **CELIS-IPS** - Platform for the production of human induced pluripotent stem cells
- Development of human induced pluripotent stem cells (iPS).
- **Histomics** - Histology platform
- Study of tissue samples.

BIOLOGICAL RESOURCE CENTER

- Samples collected during blood tests, biopsies, or other surgical actions are an extremely precious source of information in research. The ICM is home to 3 biobanks dedicated to managing these biological resources (biological samples and associated data): collecting, recording, processing, storing, and making them available to researchers.
The DNA and Cell Bank
- Biological resource center for the French Network for Multiple Sclerosis Genetic Studies (**CRB-REFGENSEP**)
- The Tumor Bank : **OncoNeuroTek**

PRISME – HUMAN BEHAVIOR EXPLORATION PLATFORM

- **PRISME - Virtual Reality** : makes virtual reality instruments adapted to cognitive and behavioral neuroscience available for use by researchers.
- The platform also develops new equipment and therapeutic protocols for neuropsychiatric illnesses.
- **PRISME - Real Life** : dedicated to the study of cognitive functions, motor performance, and social interactions in ecological environments. The platform team assists research teams in the development of adapted protocols. One of the platform's greatest strengths lies in its ability to test a large number of subjects to increase representativeness.

ICONICS BIOINFORMATICS

- Neuroscience research has seen a spectacular increase in the sheer amount of data collected in labs. The role of the iCONICS Bioinformatics silo is to collect data from various sources and ensure it is properly stored, organized, and managed with appropriate instruments to analyze it and interpret it using specialized methods and detailed statistics.
- Database and Datawarehouse
- Groups data within databases, all developed with the same structure to format and manage, on a daily basis, information from affected or healthy patients.
- Bioinformatics/Biostatistics
- Genetic and -omic (transcriptomic, genomic, epigenomic) data processing. Design and implementation of advanced methods to multimodal data integration.

DILIGENCE AND TRANSPARENCY AT THE HEART OF OUR ACTIONS

MAINTAINING A HIGH LEVEL OF EXCELLENCE IS KEY FOR ICM, WHICH IS WHY THE INSTITUTE IMPLEMENTED INTERNAL AND EXTERNAL AUDITING PROCEDURES TO ENSURE THOROUGH AND EFFICIENT MANAGEMENT: AS A MEMBER OF THE TRUSTED DONATIONS COMMITTEE AND INVOLVEMENT OF AN INDEPENDENT AUDITOR.



Financial situation in 2016 p.76

OPEN BOOKS

THE 2016 BALANCE STATEMENT SHOWS ICM AND ADREC OPERATIONS POST-MERGER FOR THE FIRST TIME. CONSEQUENTLY, THE ICM'S 2016 CONSOLIDATED BALANCE STATEMENT INTEGRATES ASSETS AND LIABILITIES FOR BOTH ENTITIES AND TAKES INTO ACCOUNT THE IMPACT OF THE BUILDING'S CONSTRUCTION, HISTORICALLY SUPPORTED BY ADREC (WITHIN A PUBLIC DOMAIN PROVISION) IN TERMS OF FIXED ASSETS AND LOANS. CASH FLOW IS ALSO ON THE RISE THANKS TO ADREC LIQUID ASSETS. THE ICM'S SCOPE OF CONSOLIDATION IN ITS 2016 BALANCE STATEMENT REMAINS HEALTHY

FUNDRAISING

15.2 M€ WERE RAISED IN 2016, AN 9% INCREASE COMPARED TO 2015.

Major patronage agreements signed with foundations or companies in 2016:

- Groupe Pasteur Mutualité to support ICM's research mission
- The Edmond J. Safra Foundation for research project funding
- Fonds Brou de Laurière, for research project funding

THE CIRCLE OF FRIENDS OF ICM BRINGS TOGETHER DONORS WHO HAVE SUPPORTED ICM FROM ITS INCEPTION, WITH DONATIONS OF 10,000€ OR MORE.

The Circle was created as a means of giving special thanks to important donors, individuals, companies, or foundations, who very actively participated in the Fundraising Campaign launched by ICM in 2008.

- At the end of 2016, the Circle had nearly **600 members**.
- Exclusive activities are organized to thank them for their support and to help donors meet and discuss with researchers, and are also a means of giving them more **in-depth information** regarding **research outlooks** and how donations are used.
- Maurice Lévy and David de Rothschild, Founding Members of ICM, currently serve as Circle co-presidents.
- In 2016, ICM organized a charity dinner at the Conciergerie in Paris on June 8, 2016, for the Circle of Friends of ICM.

OVER THE YEAR, ICM CONTINUED ITS DIRECT MARKETING STRATEGY, INITIATED IN 2010, TO INCREASE ITS DONOR BASE.

Fundraising campaigns raised 6.4 M€ over the course of the fiscal year and donor base increased to 144,000 by end of year.

Finally, ICM is especially grateful to families who collected donations in memoriam for the Institute.

IN-KIND DONATIONS AND SPONSORSHIPS

MANY COMPANIES HAVE OFFERED THEIR SUPPORT BY CONTRIBUTING SKILLS FROM THEIR FIELD, OR BY DONATING PRODUCTS FREE OF CHARGE. IN THIS SECTION ARE ALSO FEATURED ARTISTS AND COLLECTORS WHO HAVE DONATED WORKS OF ART TO BE SOLD, BENEFITING ICM.

ICM has received in-kind support within the scope of communication and fundraising activities in the form of:

- Media placement from Air France, Reedexpo/FIAC, Euronews;
- Complimentary services and products (Air France, Publicis, Orrick Rambaud Martel, Quaterback, IDEC, Moët & Chandon, Hôtel Barrière Le Fouquet's Paris, Crédit Agricole Centre Ouest).
- Luxury products, collectibles, art and other objects for the auction held during the Institute's charity auction (Enrico Navarra Editions, Akbar Padamsee, Kamel Mennour Gallery, Gérard Garouste, Gilles Le Baud, Camille Henrot, François Henrot, Fabrice Hyber, Francis Joyon, Cyril Kongo, Bertrand Lavier, Claude Lévêque, Montres FP Journe Paris SAS, Richard Mille, François Morellet, Bettina Rheims, David de Rothschild, Domaines Barons de Rothschild, Guy Savoye, Vanessa von Zitzewitz, Jean Todt, Romain Grosjean, Cité du Cinéma, Hôtel Intercontinental Paris, FIA).

ICM IN FRANCE

ICM CONTINUED ITS REGIONAL EXPANSION IN 2016. THREE REGIONAL BRANCHES (LIMOUSIN, BASSE-NORMANDIE AND AUVERGNE) WERE ORGANIZED AROUND THE FOLLOWING GOALS:

- Reinforce visibility, reputation, and attractiveness of ICM amongst donors, the general public, and economic and political figures;
- Contribute to the development of ICM's financial resources to accelerate scientific discoveries with its own research teams and regional, national and international partnerships;
- Encourage ties between ICM and regional neuroscience research partners and promote collaborations.

BALANCE SHEET


2016 RESOURCES

2016 resources reached 39.9 M€, including fiscal year products of 32.5 M€ and a carryover of allocated and unused resources from previous fiscal years of 7.4 M€. Fiscal year products are essentially made up of fundraising revenue (15.1 M€ or 46.5%), general public donations (11.9 M€ or 36.6%), companies and private foundations (3.2 M€ or 10%).

Additionally, they include:

- Revenue from technological platforms (3.3 M€), and research partnerships with industry partners (3.2 M€);
- Public subsidies (5.5 M€);
- Private subsidies (2.1 M€).

GENERAL PUBLIC FUNDRAISING
PRIVATE FOUNDATION AND CORPORATE FUNDRAISING
ACTIVITY REVENUE
PUBLIC AND PRIVATE SUBSIDIES
OTHER REVENUE



2016 APPLICATIONS

IN 2016, THE GRAND TOTAL OF APPLICATIONS REACHED 38.8 M€: 30.9 M€ USED OVER THE COURSE OF THE YEAR AND 7.9 M€ ALLOCATED FOR FUTURE USE. THE SHARE OF APPLICATIONS DEDICATED TO SOCIAL MISSIONS REACHED 24.9 M€, 81% OF TOTAL FISCAL YEAR APPLICATIONS. ICM SOCIAL MISSIONS INCLUDE:

- RESEARCH PROJECTS (55 %)
- TECHNOLOGICAL PLATFORMS (27 %)
- SCIENTIFIC EVENTS AND INTERNATIONAL PARTNERSHIP DEVELOPMENT (5 %)
- INNOVATIVE COMPANY INCUBATION (13 %)



Research project financing is primarily dedicated to nervous system diseases and spinal cord trauma. Technological platforms (neuroimaging, vectorology, genotyping sequencing, cell culture and histology) support these projects. Fundraising and communication costs (12%) represent expenses in canvassing of the general public (donations and bequests) as well as companies and private foundations (patronage and sponsorship) and communication. Operational costs (7%) represent support staff costs (finance, human resources, legal, IT and logistics). Applications on allocated resources (7.9 M€) primarily represent company and foundation donations received over the course of the year, to be utilized later for specific multi-year research programs.

ALLOCATION OF RESOURCES FROM THE GENERAL PUBLIC

RESOURCES RAISED FROM THE GENERAL PUBLIC AND USED IN 2016 TOTALED 11.9 M€.

IN SHORT, 71€ OF EVERY 100€ RAISED FROM THE GENERAL PUBLIC WERE USED TO FUND SOCIAL MISSIONS AND INVESTMENTS. 25€ WERE USED TO COVER FUNDRAISING AND COMMUNICATION COSTS, AND 4€



SIMPLIFIED BALANCE SHEET

Assets (k€)	31 12 2015	31 12 2016
Net immobilized assets	9 963	54 276
Net available and realizable assets	35 108	50 399
Total	45 071	104 675

Liabilities (k€)	31 12 2015	31 12 2016
Organization funds	19 101	44 498
Fiscal year result	766	1 191
Dedicated funds	7 464	7 919
Debts	17 740	51 067
Total	45 071	104 675

COMMENTAIRES

TOTAL ICM INVESTMENTS SINCE THE INSTITUTE'S LAUNCH REPRESENT NEARLY 24.5 M€, DEDICATED PRIMARILY TO TECHNOLOGICAL PLATFORMS SUPPORTING RESEARCH. FISCAL YEAR INVESTMENTS AMOUNTED TO 2 M€.

PRINCIPAUX INVESTISSEMENTS :

- Key equipment acquired in 2016 is a helium recycling system as well as a sequencer, for a total of 490 K€;
- Research team workspace reconfiguration and scientific equipment acquisition for 392 K€;
- Scientific IT storage capacity acquisition and calculation cluster for 737 K€.

Fixed assets amount to 54.3 M€. On December 31 2016, cash flow amounted to 28.5 M€. ICM organization funds represent 45.7 M€. This includes equity of 19.3 M€ as well as investment subsidies of 26.4 M€. Nonexpendable endowments total 1.2 M€. By fiscal year end, dedicated funds (to be allocated to various programs) amounted to 7.9 M€.

MONETARY RESERVE POLICY

ICM was supported by an 11.7 M€ grant when it was started in 2006. The board has a very cautious policy in terms of monetary reserve preservation. ICM reserves are invested in marketable securities (long-term investment contracts with major banks, capital guaranteed and 100% in euros).

IN-KIND VOLUNTARY CONTRIBUTIONS

- Volunteering: ICM was supported by volunteering over the course of the fiscal year, especially for communication campaigns in Paris and the three regional branches. Estimated volume is 1.4 yearly full-time equivalent, i.e. 37 K€ based on hourly minimum wage.

MAINTAINING A HIGH LEVEL OF EXCELLENCE IS KEY FOR ICM, WHICH IS WHY THE INSTITUTE IMPLEMENTED INTERNAL AND EXTERNAL AUDITING PROCEDURES TO ENSURE THOROUGH AND EFFICIENT MANAGEMENT: AS A MEMBER OF THE TRUSTED DONATIONS COMMITTEE AND INVOLVEMENT OF AN INDEPENDENT AUDITOR.



CODE OF TRUSTED DONATIONS COMMITTEE

On November 3, 2010, ICM received certification from the Comité de la Charte pour le Don en Confiance (Code of Trusted Donations Committee), renewed on October 6, 2016.

For over 20 years, the Committee has been a regulator of professional fundraising from the general public.

Its action is centered on 3 leading guidelines: certified organizations must respect ethics regulations, must abide by collective discipline with respect to donors, and must accept continuous monitoring of commitments.

ICM FOUNDATION - 2016 PROFESSORIT AND LOSS STATEMENT

EXERCICE CLOS LE 31 DÉCEMBRE 2016

APPLICATIONS	2016 APPLICATIONS	2016 ALLOCATION OF RESOURCES RAISED FROM THE GENERAL PUBLIC BY APPLICATION	RESOURCES	2016 RESOURCES COLLECTED	2016 RESOURCES COLLECTED AND USED
			Carryover of resources collected from general public not allocated/used at start of fiscal year		537 606
1. Social Missions	24 856 025	8 459 725	1. Resources collected from general public	11 911 067	11 911 067
Actions directly carried out			Unallocated monetary donations	10 209 784	10 209 784
Research Programs	13 717 879	2 279 528	Allocated monetary donations	321 800	321 800
Technological Research Platforms	6 805 363	2 818 012	Unallocated bequests and other gifts	780 983	780 983
Research Application and Incubator	3 144 114	2 374 195	Allocated bequests and other gifts	0	0
Other social missions	1 188 670	987 990	Other revenue from general public generosity	598 500	598 500
2. Fundraising costs	3 736 848	2 949 528	2. Other private funds	8 352 390	
Cost of appeals to the generosity of the general public	3 366 891	2 642 029	Patronage	3 127 655	
Costs related to private fund canvassing	259 861	215 989	Partnerships	3 149 193	
Communication costs	110 096	91 509	Private subsidies	2 075 543	
3. Institute operational costs	2 258 740	501 814	3. Subsidies and other public financial support	5 509 568	
			4. Other products	6 681 608	
			Financial products	442 084	
			Services rendered	3 268 019	
			Other products	2 971 505	
I. TOTAL APPLICATIONS	30 851 612	11 911 067	I. TOTAL RESOURCES	32 454 633	
II. PROVISIONS	16 835		II. CARRYOVER OF PROVISIONS		
III. PLEDGES ON ALLOCATED RESOURCES	7 859 810		III. CARRYOVER OF ALLOCATED RESOURCES UNUSED IN PREVIOUS FISCAL YEARS	7 464 986	
IV. FISCAL YEAR SURPLUS	1 191 362		IV. VARIATION OF ALLOCATED FUNDS COLLECTED FROM GENERAL PUBLIC		-1 543
V. GRAND TOTAL	39 919 619		V. INSUFFICIENT FISCAL YEAR RESOURCES		
Share of fixed assets acquired during the fiscal year financed by collected funds			VI. GRAND TOTAL	39 919 619	12 447 130
Neutralization of provisions for depreciation of fixed assets financed by collected funds					
TOTAL APPLICATIONS FINANCED BY FUNDS COLLECTED FROM GENERAL PUBLIC		11 911 067	TOTAL APPLICATIONS FINANCED BY FUNDS COLLECTED FROM GENERAL PUBLIC		11 911 067
			BALANCE OF FUNDS COLLECTED FROM GENERAL PUBLIC NOT ALLOCATED/USED END OF FISCAL YEAR		536 063
EVALUATION OF VOLUNTARY IN-KIND DONATIONS			EVALUATION OF VOLUNTARY IN-KIND DONATIONS		
Social missions	36 960		Volunteering	36 960	
Fundraising costs			In-kind services		
Operational costs			In-kind donations		
Total			Total		

COMMUNICATION AND PHILANTHROPY

YOUR GENEROUS SUPPORT AND INVOLVEMENT GAVE RISE TO AN UNPRECEDENTED SCIENTIFIC ADVENTURE. TOGETHER, YOU HAVE DECIDED TO ACT ALONGSIDE US TO IMPROVE CURRENT AND FUTURE WELL-BEING FOR MILLIONS OF WOMEN AND MEN WORLDWIDE.



LE CERCLE des amis de l'ICM *p.84*

Communication *p.86*

Thank You *p.88*

PHILANTHROPY TO SUPPORT RESEARCH

ON NERVOUS SYSTEM DISEASES

THE CIRCLE OF FRIENDS OF ICM BRINGS TOGETHER THE INSTITUTE'S MAJOR BENEFACTORS (INDIVIDUALS, BUSINESSES, FOUNDATIONS AND ORGANIZATIONS). SCIENTIFIC PARTNERSHIPS, FINANCIAL SPONSORING, EQUIPMENT DONATIONS OR SKILL PATRONAGE: SUPPORT FROM PRIVATE PARTNERS AND THE GENERAL PUBLIC'S GENEROSITY ARE KEY IN ALLOWING ICM TO INCREASE ITS RESEARCH PROGRAMS, RECRUIT THE BEST SCIENTISTS, ATTRACT YOUNG TALENT AND PROVIDE THEM WITH CUTTING-EDGE TECHNOLOGICAL EQUIPMENT. THROUGHOUT THE YEAR, PRIVATE LABORATORY VISITS ARE ORGANIZED FOR CIRCLE MEMBERS AS WELL AS SCIENTIFIC AND CULTURAL CONFERENCES AND MEETINGS WITH RESEARCHERS.

LA COLLECTE ISSUE DES LEGS ET ASSURANCES-VIE S'EST FORTEMENT ACCRUE EN 2016 POUR ATTEINDRE UN MONTANT DE 0,8 M€.

CERCLE DES AMIS DE L'ICM



LE CERCLE DES AMIS DE L'ICM
The Committee aims at rallying support to help ICM bring its ambition to life. Members are:

MEMBERS

- Lily SAFRA, Le Cercle des Amis de l'ICM
Honorary President
- Lindsay OWEN-JONES, Le Cercle des Amis de l'ICM
Honorary President
- Pr. Gérard SAILLANT, ICM President
- Jean TODT, ICM Vice-President
- Maurice LÉVY, Co-President of the Cercle des Amis de l'ICM
- David de ROTHSCHILD, Co-President of the Cercle des Amis de l'ICM
- Cédric de BAILLIENCOURT,
Jean BURELLE,
Sylvain HEFES,
François HENROT,
Jean-Philippe HOTTINGUER,
Christian SCHMIDT de la BRELIE,
François THOME,
Isabelle WEILL,
Serge WEINBERG, ICM Treasurer
Alain WICKER



IN 2016, **TWO MAJOR EVENTS** BROUGHT TOGETHER MAJOR BENEFACTORS IN SUPPORTING ICM'S FUTURE CHALLENGES:



1 IN JUNE, THE INSTITUTE ORGANIZED A GALA DINNER AT THE CONCIERGERIE, IN PARIS, WITH MAJOR BENEFACTORS
240 guests attended a dinner hosted by Stéphane Bern and took part in a recital by Natalie Dessay as well as a choreography by Marie-Claude Pietragalla and Julien Derouault, accompanied at the piano by Philippe Cassard. After dinner, an art and exceptional experiences auction was held, hosted by auctioneer Frédéric Chambre (PIASA). Thanks to the generous support of the attendees, 1.2 million € were raised over the course of the evening for ICM.



2 AN ONGOING PARTNERSHIP WITH THE FIAC CONTEMPORARY ART FAIR WITH THE "ART AND SCIENCE" BREAKFAST
Professor Marie Vidailhet, neurologist, Jennifer Flay, FIAC Director, researcher and team leader at ICM along with artists Camille Henrot, Jean-Sébastien Leblond-Duniach, countertenor Sébastien Fournier and choreographer Florence Guérin shared their vision of movement disorder with the Institute's Founding Members and event host Claire Chazal. Over 300,000€ were raised over the course of the morning to support ICM research.

YOUR SUPPORT IS ESSENTIAL

SEVERAL EVENTS TOOK PLACE DURING THIS PAST YEAR ALREADY FILLED WITH EXCITING SCIENTIFIC PROGRESS.



Among these was the tenth “Future Research” program graduation ceremony; “The Brain to Market” Summer School combining neuroscience and entrepreneurship on the topic of epilepsy, and the Dublin presentation of “The Move” program, that uses miming to teach neurological semiology to medical school students.



Various communication efforts were carried out during the National Neurodegenerative Illnesses Days, both towards Institute donors and the general public. These efforts were an opportunity to cement ICM’s role as a major player in nervous system diseases research and position it as a key contact for media inquiries.



F.P. Journe renewed its commitment to donate 5% of proceeds on each sale of the Centigraphe Souverain Watch to ICM.



IDEC has chosen to display ICM logo on its Maxi Trimaran

THEY SUPPORTED ICM

FEE RARISSIME LE LIONS CLUB DES ESSARTS-LE-ROI 20 KM DE PARIS
 LIONS CLUB BLOIS DOYEN LIONS CLUB BLOIS RENAISSANCE
 LIONS CLUB CHAMBORD DELIA LIONS CLUB CLASSIC DAYS
 UN CHRONO POUR UN DON GÉRARD CROTTI DE VERRIÈRES LE BUISSON
 MUSIC PASSION COGNO-BOURDIEU PIERRE MOREL LORS DU TOUR AUTO
 PARKINSON ECOLE SAINT JEAN DE PASSY Un circuit pour le cerveau
 JACQUES-NICOLAS DE WECK POUR FÉDÉRATION FRANÇAISE POUR LE DON DE SANG BÉNÉVOLE DE ST MAUR
 LIONS CLUB DE MONTLERRY SOGNO DI ET LE ROTARY CLUB DE SAINT MAUR
 Lions Club Lyon Doyen CAVALLINO Internationaux de Strasbourg Porsche Club Motorsport

REGIONAL DELEGATIONS

ICM researchers collaborate with several regional teams. Shared research projects are focused on three illnesses: Frontotemporal lobar degeneration (FTLD) in Caen (Basse-Normandie), Amyotrophic Lateral Sclerosis in Limoges (Limousin), and spinal cord damage in Clermont-Ferrand (Auvergne).

ICM ON THE OUTSIDE

« MENTAL DÉSORDRE »
 À LA CITÉ DES SCIENCES ET DE L'INDUSTRIE
 CHARITY DAY BGC
 20KM DE PARIS
 « 48H POUR FAIRE VIVRE DES IDÉES »
 LE MAXI TRIMARAN IDEC À LA CONQUÊTE
 DU TROPHÉE JULES VERNE
 TROPHÉE LES ECHOS
 COURSE DES HÉROS
 S3ODÉON
 « MUSIQUE & CERVEAU »
 VIVA TECHNOLOGY
 SEMAINE DU CERVEAU
 COLÈRES PLANQUÉES
 TOUR DU LAC DE VASSIVIÈRE

“ICM’s vision has always meant a lot to me. One day, we will lean the brain’s secrets thanks to the hard work of women and men who are dedicated to gaining a deeper understanding of neuroscience and to furthering medicine. I am proud to have supported ICM from the start with the yearly planning of the 20 KM de Paris, with a booth in the race village, an annual donation as well as complimentary race bibs for researchers. ICM’s mission is innovative and ambitious: it deserves all the support possible not only for research, but also to improve patient care and everyday life. Congratulations to the whole team for this unparalleled human and scientific adventure.”

DIDIER ECK
 President of the 20 KM de Paris Association



THANK YOU

MAJOR PATRONS

Maria Rosa Bemberg
 CARCEPT PREV - IPRIAC - KLESIA
 FIA FOUNDATION FOR THE AUTOMOBILE
 AND SOCIETY
 FONDATION BETTENCOURT SCHUELLER
 FONDATION EDF DIVERSITERRE
 FP JOURNE - INVENIT ET FECIT
 FONDATION E. J. SAFRA
 HSBC France
 Lily Safra
 Docteur Léone Noëlle Meyer
 OCIRP
 ORRICK RAMBAUD MARTEL
 Lindsay Owen-Jones
 PUBLICIS
 RACE OF CHAMPIONS
 Edouard et Martine de Royère
 Michael Schumacher
 1 anonymous

MAJOR BENEFACTORS

AIR FRANCE
 Famille Jan Aron
 Elisabeth Badinter
 Luc Besson
 BOUYGUES
 Lucienne Collin
 FEDERATION FRANCAISE DU SPORT
 AUTOMOBILE
 FONDATION AREVA
 FONDATION ARPE
 FONDATION COGNACQ-JAY
 FONDATION D'ENTREPRISE MICHELIN
 FONDS DE DOTATION PIERRE BERGE

M. et Mme Jacques Garaialde
 GROUPE PASTEUR MUTUALITE
 GROUPE IDEC
 Sylvain et Michèle Héfès
 François Henrot
 M. et Mme Alain Joly
 Serge Kampf
 Christiane Laborie et Roger Lionnet
 Maurice Lévy
 Dominique et Danièle Mars
 Richard Mille
 ORACLE
 PATHÉ
 PHILIPPE FOUNDATION, INC.
 RATP
 David de Rothschild
 SCHNEIDER ELECTRIC
 Claude Sfeir
 Jean Todt et Michelle Yeoh
 Serge Weinberg
 1 anonymous

BENEFACTORS

Benoit Abdelatif - Classic Days
 ACCOR
 AMAURY MEDIAS
 Christine André
 Yvon André et Annette Gellé
 ASSOCIATION DEMAIN DEBOUT
 ASSOCIATION RMC BFM
 ASSOCIATION SOGNO DI CAVALLINO
 ASSOCIATION SPORTIVE ET CULTURELLE
 DE L'AIR
 M. et Mme Guy Autran
 AXA RESEARCH FUND
 AXERIA PREVOYANCE

BANQUE PICTET
 Anne Bardinon
 Jean-Paul Baudecroux
 BGC PARTNERS
 Gérard Bertinetti
 Christian et Marie-Claire Blanckaert
 Marie-Claire Blanckaert
 M. et Mme Pascal Boileau
 BOLLORÉ
 BOREL & BARBEY
 Irène Bonnet
 Micheline Bridel
 Famille Bucaille
 Jean et Anne-Marie Burelle
 Louis Camilleri
 CAMPENON BERNARD CONSTRUCTION
 CAPGEMINI
 Marella Caracciolo Agnelli
 P. et J.P. Carle
 Olivier Carre
 Patrick Charpentier
 Suzanne Charpentier
 M. et Mme Léon Cligman
 COMITE NATIONAL OLYMPIQUE
 ET SPORTIF FRANCAIS
 CREDIT AGRICOLE D'ILE-DE-FRANCE
 MECENAT
 CREDIT MUTUEL NORD EUROPE
 CREPA RETRAITE
 Jean-Patrice et Marie-Anne Dalem
 M. et Mme Laurent Dassault
 DAVID HERRO TRUST
 Claude Demole
 Aline Derbesse
 Jean-Louis et Marie-Cécile Dufloux
 Michel Duhoux
 Rena et Jean-Louis Dumas

Marcel Dupuis
 Claude Félix
 FERBLANC FUNDRAISING
 Emilio Ferré
 FINETFO SA
 FONDATION AIR LIQUIDE
 FONDATION MARIE-ANGE BOUVET
 LABRUYERE
 FONDS PATRICK DE BROU DE LAURIERE
 Dimitri et Maryvonne Fotiadi
 Marie-Pierre Fournier
 Jean-René Fourtou
 GROUPE G7
 GALORI TRUST
 GIULIANI S.p.A
 GLAXO SMITH KLINE
 Mina Gondler
 GROUPE EMERIGE
 GROUPE LUCIEN BARRIERE
 GROUPE PREVOIR
 Monique Guérinat et FISA
 Mireille et René Hadjadj
 Pierre Hanriot
 Jean-Marie et Laurence Hennes
 HUMANIS
 IWC SCHAFFHAUSEN
 LILLY
 Marie-Jeannine Jacobson
 Alain Kahn
 M. et Mme François Lafon
 Bernard Lange
 Bertand Lavier
 LES AMIS DE CAPUCINE
 Martin Lebeuf
 Angélique Lenain et Fabrice de Gaudemar
 LIGUE DE FOOTBALL PROFESSORSSION-
 NEL
 Georges Louviot
 Florent Menegaux
 M. et Mme Bertrand Meunier
 Eric et Hervé Neubauer
 Novalis
 Gilles et Sylvie Péllisson
 Jean-Luc Petithuguenin
 PHILIP MORRIS INTERNATIONAL
 Jacques Popper
 Christian Poquet
 Claude et Benoît Potier
 RELAIS & CHATEAUX
 Jean Reno
 Jean-Paul Ringear
 ROTHSCHILD & CIE BANQUE
 Nelly Rouyrès
 RSI PROFESSORSSIONS LIBERALES ET
 ARTISANS
 Hubert Saltiel
 Guy Savoy

SODEXO
 SOLIDAIR'S
 Jean-Cyril Spinetta
 Yannick Tarondeau
 Jean-Philippe Thierry
 François Thomé
 Albert Uderzo
 Thierry Varène
 Antoine Virgili
 Dominique Vizcaino
 YVES ROCHER
 Famille Yoël Zaoui
 15 anonymous

DONATORS

Benoit Abdelatif
 Pascal Abensour
 ACCURACY
 ALAIR & AVD
 Colette Amram
 Marie-José Alfandari
 M. et Mme Emmanuel Allard
 Jean-Luc Allavena
 Benoît André
 Philippe André
 Christine André
 ARTEMIS
 ARB CONSEIL SAS
 ASSOCIATION JEAN-CLAUDE DUSSE
 ASSOCIATION MUSIC PASSION PARKIN-
 SON
 ASSOCIATION PAUL ET PHILIPPE PERROT
 ASSOCIATION SOGNO DI CAVALLINO
 ASSOCIATION SPORTIVE ET CULTURELLE
 DE L'AIR
 ASSOCIATION VIVRE A SAINT DAMIEN
 Jean-Pierre Aubin
 Aurel BGC
 AUTOMOBILE CLUB DE FRANCE
 M. et Mme Guy Autran
 Nicole Ayanian Schneider
 Solange Bakalowicz
 BANQUE DE LUXEMBOURG
 Frédéric Banzet
 M. et Mme Pierre-René Bardin
 M. et Mme Rémy Baschet
 Laurent Baud/TECHNOMARK
 M. et Mme Claude Baudon
 M. et Mme Thierry Benderitter
 M. et Mme Arnaud Benoist
 Robert Bensoussan
 Fernande Benveniste
 Gérard Bequin
 Claude Berda
 BERNARD MIRABAUD ENERGIE
 M. et Mme Jacques Bernier
 Anne et Raymond Bert
 Gérard Bertinetti
 BIOCOCODEX
 Jean-Claude Biver
 Alain et Blandine Bizot
 Gaby Blum
 BMENERGIE
 M. et Mme André Bohm
 Hubert Boinet
 Tatiana et Adrien de Boisanger
 M. et Mme Philippe Boitet
 Chantal Bolloré
 M. et Mme Michel Yves Bolloré
 Irène Bonnet
 Jean-Marie Borzeix
 Francis Bossu
 Yves Boucheny
 Monique Bourven
 M. et Mme Thierry Bourvis
 Jean Bousquet
 Claude Bouygues
 Renaud Bouygues
 Jean-Jacques Branger
 François Brière
 M. et Mme Jean-Jacques Brunet
 Famille Bucaille
 M. et Mme Etienne Burdin
 Jean et Anne-Marie Burelle
 Dr André Buyse
 M. et Mme Alain Candelier
 François Canellas
 Marie-Noëlle Canu-Duclert
 M. et Mme Arnaud Caspar
 CB RICHARD ELLIS
 CELIO
 CHAMPAGNE LAURENT-PERRIER
 MOET & CHANDON
 Jean-Bernard Champeau
 Patrick Charpentier
 Suzanne Charpentier
 Didier Chartier
 Pr Christian Chatelain
 Amaury et Alix de Chaumont Quiry
 Dominique Chedal
 Jean-Loup Cherel
 Dr André Chérot
 Brigitte Chichignoud
 Prince et Princesse de Chimay
 Fabien Chone
 Philippe Clément
 Jean-François Colin
 Gérard Collet
 Bertrand Collomb
 Alberto Colussi
 COMBATTRE LA PARALYSIE
 Françoise de Combret
 COTY INC.

Mme Dominique Coulon-Temkine
 M. et Mme Robert Counoy
 Charlie Coutouly
 CREDIT AGRICOLE CENTRE OUEST
 CREDIT MUTUEL NORD EUROPE
 Françoise Crouzet
 Jean-Patrice et Marie-Anne Dalem
 Olivier Dassault
 Laurent Dassault
 Jean-Luc Davesne
 Vicomte Olivier Davignon
 M. et Mme Jean de Balquet du Chayla
 Charles de Boisriou
 Christiane de Cherisey
 M. et Mme Philippe Déboudé
 Annette Decroix Lavaur
 Famille Dehove
 Guy Delarue
 Ghislaine Delattre
 Jean-Louis Delvaux
 Micheline Deschamps
 M. et Mme Patrice Diehl
 Danielle Dubuit
 Jean-Louis et Marie-Cécile Dufloux
 Jean-Philippe Dugue
 Jacques Dumas
 M. et Mme Claude Dumas Pilhou
 Michel Dupuis
 Marcel Dupuis
 Henri Dura
 Cécile et Christophe Durand-Ruel
 Mohamed El Babsiri
 M. et Mme Claude Elmaleh
 EMERAUDE INTERNATIONAL
 ERIC HOLDING
 GROUPE EMERIGE
 Gérard Erstein
 Jacques-Arthur Essebag
 EXELGYN SA
 Eliane Exbrayat
 Olivier et Nathalie Favre
 Amélie Fayet
 FEDERATION FRANCAISE DE TENNIS
 FEDEX CORP
 Claude Félix
 FINANCIERE DE L'ECHIQUEUR
 FINANCIERE POCH
 FERBLANC FUNDRAISING
 Roland Fernet
 Charles-Henri Filippi
 Jean-Claude Meyer
 Thierry Flecchia
 Jean Floresco
 Fondation Plenum
 FONDATION VENUE PRIVEE
 Philippe Foriel-Destezet
 FONDS DE DOTATION LIONS CLUB LYON

DOYEN
 FRANCE GALOP
 M. et Mme Fredouille
 Patrick Fuchs
 GAGNERAUD PÈRE & FILS
 André Gaubert
 Bernard et Denise Galambaud
 Jeanne Galli
 GALOA
 M. et Mme Gilles Gantois
 Philippe Genève
 Marie-France Geoffroy
 Francis Thomas Gleeson
 GLG Partners
 Christian Gloz
 Alain Goffi
 JeanFrançois et Dominique Gouédard
 M. et Mme Pierre-Henri Gourgeon
 Allan Green
 GROUPE BABILOU
 GROUPE LHOIST
 Jérôme Guerrand-Hermès
 Pierre Guichet
 Catherine Guillouard
 Vivien de Gunzburg
 Christian Haas
 Mireille et René Hadjadje
 Marc Haerberlin
 Maria Halphen
 M. et Mme Thierry Hannecart
 Pierre Hanriot
 Bob Harifin
 Maryse Hasselmann-Gérard
 Gérard Haution
 Jean-Claude Heili
 Camille Henrot
 Alice Henry-Mairiniac
 Paul Hermelin
 Brigitte Hidden
 Violette Hirsch
 M. et Mme Bernard Hours
 HUNTINGTON ESPOIR OUEST
 Jean-Pierre Hutin
 Eve Icole
 IMPALA SAS
 M. et Mme Jean Iribarren
 Robert Jamain
 Christophe Karvelis Senn
 Pierre Jardinier
 JEAN ACHE S.A.
 Alain Kahn
 Michael Kennedy
 Cyril Kongo
 Daniel Kouzo
 Sophie et Frédéric Krebs
 M. et Mme Pierre Kuhn
 M. et Mme Patrice de Laage de Meux

M. et Mme Antoine Labbé
 LABORATOIRE ECLAIR
 Michel Labouret
 Jean-François Labrousse
 M. et Mme Michel Lacoste
 Réjane et Michel Lacoste
 M. et Mme Etienne Lafon
 Pauline Lamonica
 Bernard Lange
 Christian Langlois-Meurinne
 Jacques Larcher
 FONDS PATRICK DE BROU DE LAURIERE
 Philippe Lassus
 Alain Lazimi
 LE CHEVAL FRANÇAIS
 Martin Lebeuf
 Anne Le Lorier
 Bernard Lefebvre
 Patrick Lefort
 Angélique Lenain et Fabrice de Gaudemar
 LES VOILES DE SAINT BARTHE
 Maurice Lesaffre
 Haim Leshanot
 Nicolas Lescure
 Jean-Jacques Lestrade
 Hubert et Catherine Lévy-Lambert
 LIONS CLUB DES ESSARTS
 Jacques et Irène Lombard
 Marie-Thérèse Lombard
 L'Oréal
 Francis Lotigie-Browaey
 Daniel Louppe
 M. et Mme Yves Loussouarn
 Claudine Luciani
 M. et Mme Pierre Magnant
 Marie France Malezieux Blicq
 Hugues et Jocelyne Mallet
 Bob Manoukian
 François Manset
 Gilles de Margerie
 M. et Mme Hervé Margolis
 Monsieur Marinopoulos
 M. et Mme Patrick Martin-Michaud
 Pierre Martinet
 Bruno Matheu
 Yves Mathieu
 Bernard Maurel
 Florent Menegaux
 Philippe Meignan
 Alain Menoncin
 MILLE MERCIS
 Thierry et Natacha Millemann
 François Momboisse
 Maylis de Montgolfier
 Gérald Mourand
 Bernard Moreau
 Daniel Moreau

Georges-Michel Mouries
 Renée Mullie
 Jean Claude Muret
 Isabelle Murray
 Yves Néron-Bancel
 NEUROLIGUE
 Jack Noirtin
 NOVARTIS
 Nahed Ojeh
 Jacques Olivier
 ONDRA PARTNERS
 Jérôme Paris
 René Pascal
 David Pastel
 Philippe Pataud
 Guy Paucot
 Daniel Payan
 M. et Mme Claude Peaudeau
 Valérie Péresse
 Claude Pequart
 Guy Percie du Sert
 Jacques Pericchi
 Michel Pernot
 Jacques Perrin
 Jean Peter
 Laurent Pétin
 Jean-Luc Petithuguenin
 ORKYN'
 M. et Mme Patrice Piccon
 Luciano Pietropoli
 Yves Pignet Ruinet
 Janine Pion-Goureau
 Caroline et Olivier Plantefève
 PMU
 M. et Mme Henri de Ponnat
 POTEL & CHABOT SA
 Benoît Potier
 Philippe Pourchet
 PRODUCTION ET MARCHÉS
 Jean de Quatrebarbes
 Bernard Quetier
 Jean-Paul Rabache
 Françoise Rabouin
 Paul Raingold
 M. et Mme Patrick Rannou
 Alain Ranval
 Alain Rauscher
 M. et Mme Jean-Pierre Raynal
 Christian Revol
 Laurent Richier
 RICOL, LASTEYRIE & ASSOCIES
 Philippe Rinczaux
 Jacques et Annie Riou
 Christine Rivet
 Simon Robertson
 Aldo Robotti

Bruno Roger
 ROMEO SA
 Patrick Roque
 Jean-Jacques Rosa
 Martin Rosdy
 ROTARY CLUB ORLEANS VALDELOIRE
 ROTARY CLUB TOULOUSE SUD
 Richard Roth
 Elisabeth de Rothschild
 Louise de Rothschild
 M. et Mme Bernard Rouer
 Thierry Roussel
 Nelly Rouyrès
 M. et Mme Ruckstuhl
 Igor Rybakow
 Jean-Pierre Sabardu
 Hubert Saltiel
 Claire Sarti
 Guy Savoy
 Patrick Sayer
 M. et Mme Christian Schlumberger
 M. et Mme Pierre Schule
 Colette Schumacher
 Claude Schweisguth
 SICA2M
 SFR
 François Silvestre de Sacy
 Gérard Simmat
 SOCAUSUD
 SOPAREXO
 SOLIDAIR'S
 SORIN GROUP
 Claudine Soubrie
 Marc Soulé
 SPEB
 SPEBI
 Eric Spielrein
 Giuliana Spotorno
 STADE FRANCE
 Henry Stanislas
 M. et Mme Vincent Strauss
 Alain Tachot
 Claude Taittinger
 Yannick Tarondeau
 Henri de Termont
 Pascal Tetard
 Alain Thinot
 Docteur Martine Thomassin
 TRACE ONE
 Janine Tristant
 Nicolas de Turckheim
 M. et Mme Guy Ullens
 Isabelle Valeani-Portes
 Edith Vansteenbergh
 Thierry Varène
 Patrick Vegeais
 VERTU

M. et Mme Gilbert Vidal
 Corinne et Ramon Villagrasa
 M. et Mme Guillaume Vincenot
 VINCI CONCESSIONS
 Gérard Viquel
 Antoine Virgili
 Olimpia Weiller
 M. et Mme Wierre
 Charles Moore Wilson
 Brigitte Wolff
 XO EDITIONS
 ZENITHOPTIMEDIA
 Gérard Zimmerlin
 Vanessa Von Zitzewitz
 75 anonymous

ICM volunteers

Antonio Lopez
 Annie Wilson
 Nicole Fourn
 Ariane Bucaille
 Marie-Claude Theguet
 Pascale des Abbayes

